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ABSTRACT 
 Detection and quantification of molecules has an enormous importance 
and potential in the field of scientific development and basic discovery research. 
Advances in colorimetric techniques, fluorescent labeled probes and biosensor 
based technologies have resulted in the specific detection and precise 
quantification of analytes. The effective development of a particular detection 
method needs optimization in terms of overall speed, efficiency, and accuracy of 
the sensing system. Current biosensor approaches often rely on cumbersome 
procedural steps and reagent requirements. Along with the complexity of the 
assay, the size of the analytical instrument is a deterrent factor for on-site 
applications. To overcome such disadvantages, novel approaches that challenge 
traditional methods need to be developed. Today, technological advancements 
have enhanced the ability of researchers to change the properties of molecules. 
An in vitro selection and amplification technique, called SELEX, has allowed for 
the discovery of specific oligonucleotide sequences referred to as 'aptamers'. 
Synthetic oligonucleotide aptamers display a high specificity and affinity binding 
to different classes of target molecules. Aptamers can discriminate between 
closely related targets with subtle structural differences. Currently, considerable 
efforts are being applied to miniaturize the nucleic-acid based sensor systems 
and assays for analytical and diagnostic screenings based on fluorescence 
approaches, calorimetric detections and other biosensing methodologies. The 
efficacy of aptamer based biosensors has been shown on a number of 
biosensing platforms and these sensors can provide revolutionary sensitivity for 
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forensic detection and identification of controlled substances. Most of the 
aptamers used in sensor technologies are modified post selection for their use in 
analytical, diagnostic, forensic and therapeutic applications. Here we detail the 
specificity profile of cocaine aptamer including a range of metabolites such as 
benzoylecgonine (BZE), ecgonine methyl ester (EME), ecgonine ethyle ester 
(EEE), ecgonine (ECG), cocaethylene (COE), norcocaine (NOR) and 
anhydroecgonine methyl ester (AME). We tested different variants of cocaine 
aptamer and determined that the specificity of the aptamers is wider than 
previously reported. The cocaine aptamer binds to cocaine COC, NOR and COE. 
Extremely weak affinity was observed for BZE. All variants of cocaine aptamer 
tested showed uniform specificity but different affinities. We determined the 
motifs of the cocaine that are important for aptamer recognition. We 
hypothesized that if the cocaine aptamer binds selectively to cocaine and some 
of its metabolites then the functional groups that are common to these ligands 
should indicate the determinants of aptamer recognition. The affinity of the 
aptamers was tested against  cocaine and its natural metabolites and against the 
unnatural cocaine molecules such as cocaine-tertiary-N-biotin (GK69), cocaine-
tertiary-N-Boc (GK68), amethyl cocaine (GK71), dithiomethyl cocaine (GK94) 
and dihydroxy cocaine (GK66).  It was determined if the aptamer recognition of 
cocaine dependent on the functional groups of cocaine such as benzoyl ester, 
methyl ester and N-methyl group and also upon the underivitized part of the 
cocaine molecule. The information of the functional groups important for aptamer 
recognition will be helpful towards the design of aptamer based analytical 
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methods where the knowledge of steric aspects, such as the geometric shape, 
and  interaction with the functional groups, plays an important role. For diagnostic 
and analytical assays, such information will help in predicting the ligands that 
have the potential to cross react, depending upon their structural similarity with 
cocaine. Further, we report a novel method for the fluorescence based detection 
of cocaine and cocaine metabolites using a 2-aminopurine (2AP) modified 
cocaine aptamer. Fluorescence quenching of the 2AP upon cocaine binding was 
used to detect cocaine and its metabolites. 2AP is a structural analogue of 
adenine in which the amino group is located at the C2 position instead of the C6 
position. 2AP is an important molecule owing to its fluorescence properties and 
has been used as a reporter in structural studies of oligonucleotides. This 
molecule  is reported to form structurally and thermodynamically similar Watson 
Crick base pairs with thymine as adenosine. We tested several 2AP substitutions 
of the cocaine aptamer that provided different fluorescence quenching and 
affinity profiles. Substitution of 2AP for A at the 23rd position was best suited for 
the fluorescence detection of cocaine and metabolites in homogeneous samples 
including 10% urine. Interestingly, 2AP substitution at the 6th position increased 
the affinity of the cocaine aptamer. The increase in affinity of the aptamer upon 
2AP substitution could be due to the perturbation of the aptamer structure by 
2AP or to direct interaction of 2AP with the cocaine. The cocaine aptamer has 
been reported to undergo large structural changes upon cocaine binding. 
However, in our studies we found relatively small 2AP fluorescence changes in 
the regions of the aptamer reported to undergo large changes. While the cocaine 
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aptamer can be used for the detection of cocaine and metabolites in 
homogeneous solutions, the forensic application of this aptamer, especially the 
detection of cocaine in urine is limited due to its specificity profiles and its low 
binding affinity.  
 
Key words: Aptamer, cocaine, aptamer specificity, 2-Aminopurine, aptasensor.  
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CHAPTER I: Introduction and objectives 
 
 The abuse of cocaine remains a major challenge for public health 
authorities and law enforcement agencies. There is a continuous demand to 
improve and develop advanced screening methods for detection and 
quantification of cocaine, its metabolites and other controlled substances. The 
currently used conventional biodetection systems for cocaine have several 
shortcomings that include their physical size, need for laboratory settings, high 
cost of equipment, large and multistep process of sample preparation, slow 
analysis and lack of simultaneous detection of the full range of cocaine and its 
metabolites. Against the backdrop of current testing technologies available for 
cocaine detection, the potential of aptasensors for detection of cocaine and its 
metabolites is immense. Aptamers are becoming an important biological 
component in biosensors. Synthetic oligonucleotide aptamers display a high 
affinity binding to recognize virtually any class of target molecules and can often 
discriminate between closely related targets. The in vitro methods for selection of 
aptamers, chemical synthesis, on demand modification, structural stability, 
reusability, high throughput, reduced cost, minimized material consumption and 
their ability to multiplex have identified aptamers as very valuable tools to fill in 
the gaps existing in current sensing platforms. The synergism between aptamers 
and fluorescence based technologies offer a low cost aptasensing detection 
platform for sensitive and specific detection of cocaine and it metabolites.  
The current research is designed with the following objectives:  
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1. Development of fluorescence based portable, low cost and robust 
aptasensor for specific, sensitive, rapid, real time detection of 
cocaine and its metabolites in solution and unprocessed biological 
samples such as urine. 
2. Determine the specificity and ligand recognition pattern of the 
unmodified and 2AP substituted cocaine aptamer for cocaine and 
its metabolites.  
 
The successful completion of this research will set the stage for the 
development of aptasensing platforms with 2-aminopurine modified aptamers for 
detection of cocaine. Determination of the specificity of the cocaine aptamer for 
cocaine and cocaine metabolites will provide a means to obtain information 
regarding their concentrations in biological samples for more accurate clinical 
and forensic interpretations. 
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CHAPTER II:  Review of literature 
2.1 Cocaine in perspective 
The use of cocaine has a history dating back to the Spanish conquest of 
North America, and to its laboratory isolation by Freidrich Gaedcke in 1855. 
Cocaine (benzoylmethylecgonine) is a crystalline tropane alkaloid derived from 
leaves of Erythroxylum coca [1]. It is a benzoic acid ester of nitrogen containing 
ecgonine. The first reported use of cocaine as an anesthetic was in 1975 [2]. 
Cocaine is a powerful, psychoactive and addictive central nervous system 
stimulant that is classified as a Schedule II drug [3].  Injecting, snorting, and 
smoking are the most common routes for administration of cocaine. The use of 
cocaine leads to adverse health consequences such as severe paranoia, acute 
cerebrovascular and cardiovascular emergencies, increased risk of HIV/AIDS 
and in many cases, the death. The National Survey on Drug Use and Health 
(NSDUH) in 2007 reported dependence and regular abuse of cocaine by 1.6 
million Americans.  In the year 2008 NSDUH reported that 5.3 million Americans 
of age 12 and older had abused cocaine in some form at some time of their lives. 
At least 2% of all cocaine users were under the age of 14 years (Rothman et al. 
2001). In the year 2010 NSDUH further reported that 637,000 persons of ages 12 
years and older had initiated using cocaine, during the preceding one year 
period, at a rate of about 1,700 new persons per day. Cocaine remains the 
leading cause of emergency hospital visits and illicit drug-related deaths such as 
homicide, suicide and accidents in the United States [4-6]. The use of cocaine 
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costs the national economy billions of dollars in terms of lost productivity, law 
enforcement, and added medical expenditures due to perinatal and prenatal 
complications in mothers exposed to cocaine during pregnancy [7]. Neonates of 
cocaine abusing mothers display severe neurobehavioural disorders and delayed 
development [8,9]. The long term effects in terms of IQ (Intelligence quotient) 
levels of children are detrimental for the nation in terms lost intellectual 
manpower. Lower IQ scores and language performance in cocaine-exposed 
children cost the economy 350 million dollars annually in terms of special 
education services that are rendered to such children [4]. No less damaging are 
the socio-cultural effects of cocaine, which include the loss of family structure 
and child neglect [10]. Due to the wide spanning and hazardous effects of 
cocaine, it is a constant endeavor of the scientific and drug enforcement 
authorities to address this colossal problem on all fronts. Advances have been 
made with the advent of drugs  [11] and vaccines [12-14] for treatment of cocaine 
addiction [15-18]. Amongst all strategies to counter the problem of cocaine, of 
prime importance remains the prevention of its widespread use through the 
development of efficient analytical procedures for the detection of cocaine in 
biological and other samples [19]. Law enforcement authorities need to be armed 
with simple and sensitive technologies for the detection of cocaine on the streets 
to prevent its trafficking into and across the United States [20]. Such detection 
methods should also be readily available for the diagnosis, detection and 
therapeutic purposes.  Consequently, detection systems should uphold the legal 
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validity of results and the integrity of the samples should be preserved post 
testing by detection technologies [21].   
2.2 Current methods to determine cocaine 
2.2.1 Sensitivity, specificity and biological matrices  
The ideal method for detecting cocaine should be cost effective, sensitive, 
specific, rapid and should detect cocaine or its metabolites in complex matrices 
and unprocessed biological samples  [22]. The forensic analysis of cocaine, 
especially in terms of time of exposure to cocaine, requires that cocaine be 
determined in diverse matrices such as blood, hair, saliva, plasma, internal 
organs, meconium, urine, nails, teeth, sweat and amniotic fluid etc [23-25]. Urine 
remains the biological matrice of choice because it can be obtained non-
invasively and it contains detectable concentrations of urine and its metabolites 
[26]. Evaluation of urine for cocaine or its metabolites gives an objective index of 
cocaine use [27]. The available cocaine aptamer has been reported to maintain 
its specificity for cocaine in fetal bovine serum [28,29]. Extremely high sensitivity 
is also desired for the detection techniques if cocaine or its metabolites have to 
be detected in pg/mg of hair extracts or ng/ml in other samples of forensic 
interest. It has been recognized that the low sensitivity of the existing cocaine 
aptamer, with a Kd in the micromolar range, is a constraint because for effective 
forensic applications the aptamer should have sensitivity in the picomolar range 
[30].  
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Biological matrices provide an important challenge for the development of 
sensitive and specific detection systems. Biological matrices have a complex 
composition and the analyte of interest may be present in extremely low 
quantities depending upon the time of exposure to the drug. Matrix interference 
either involves signal suppression or enhancement. False negative results due to 
reduced sensitivity of the test or false positives due to lack or specificity may 
result from co-extraction of compounds having similar physicochemical 
properties. The cross reactivity is often seen, due to structural similarity, with 
concomitant administration of opioids, barbiturates and benzodiazepines along 
with cocaine [22,31,32]. Specific and sensitive detection is also important 
because street drugs are mostly adulterated and have an uncertain composition. 
For example, heroin can be adulterated with phenobarbitone, methaqalone, 
quinine, acetylcodiene or lignocaine and may also need to be differentiated from 
amphetamines or cocaine.  
Urine remains the biological sample of choice for detection of cocaine and 
its metabolites due to its ease and non-invasive nature of collection. Most of the 
commercially available kits use urine for cocaine detection. The sensitivity and 
specificity of immunoassays for detection of cocaine or its metabolites in urine 
samples is a challenge because urine samples are frequently and sometimes 
deliberately contaminated with bleach, soap or salt to disrupt the immunoassays. 
Sensitivity of assay is also of significance when very low concentration of 
analytes have to be determined in test samples [33]. Sensitivity of the assay 
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becomes more vital when different drugs can have common metabolites. Heroin 
along with morphine, or ecgonine with ergot produce common metabolites in 
urine and in such cases differentiation relies upon the ability to detect unique 
metabolites of parent compounds which may be present in extremely low 
concentrations [34]. The detection system should also be able to differentiate 
between structurally similar drugs of abuse as in the case of morphine and its 
congeners such as codeine and heroin etc. Cocaine is a non-polar molecule with 
a biological half life of 30-90 minutes. Due to the short half life of cocaine, the 
metabolites of cocaine gain importance for detection due to their comparatively 
longer half lives. Some of the important metabolites of cocaine include the 
hydrophilic benzoylcocaine (BZE), ecgonine methyl ester (EME), ecgonine 
(ECG) and norcocaine (NOR). Cocaine is excreted in urine as benzolycocaine 
(35-45%), ecgonine methyl ester (32-49%), ecgonine and as unaltered cocaine 
(1-9%) [35,36]. Benzoylcocaine (BZE) is an important marker for cocaine in urine 
and can be easily detected in urine for up to 72 hours. Compared to the 30-60 
minute elimination half life of cocaine in urine the half life of benzoylecgonine is 6 
hours, which makes it a preferred metabolite for the detection of cocaine [37,38]. 
2.2.2 Non-immunoassay based detection methods for cocaine and its 
metabolites 
A number of methods with varying sensitivity and specificities are currently 
employed for qualitative and quantitative analysis of cocaine or its metabolites. 
Cocaine and its metabolites are almost always confirmed using liquid 
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chromatography–mass spectrometry (LC-MS) [39-44]. Gas chromatography with 
mass spectrometry (GC-MS) is also a powerful technique for unequivocal 
identification of cocaine in urine, teeth and other biological samples [24,25,45-
47]. The disadvantage of mass spectrometric techniques is the effect of the 
matrix from which the analyte has been extracted. The analyte of interest is often 
used after purification by thin layer chromatography [34]. Jufer et al, 2000, using 
the HPL-MS, analyzed the urine samples from six cocaine users [48]. The 
subjects were healthy males who self-reported that they have been using 
cocaine for at least two times a week during the last six weeks, by either smoking 
or by the intravenous route.  The authors reported the urinary concentrations of 
3.0±0.6, 13±1.6, and 9.0±1.9 µM for cocaine, benzolyecgonine and ecgonine 
metyl ester, respectively. Similar findings have been reported by Wang et al., 
1994 [49]. The authors collected specimens from healthy volunteers with a 
history of drug abuse and reported the mean concentration of 0.3±0.5, 17±11, 
and 5.0±4.8 µM for cocaine, benzolyecgonine and ecgonine methyl ester, 
respectively.  
Another technique of interest to forensic analysis is Solid Surface Room 
Temperature Phosphorimetry (SS-RPT) which is a rapid, cost effective, sensitive 
and selective technique for detection of cocaine. Solid surface room temperature 
phosphorimetry (SS-RPT) is used for detection of cocaine and benzoylecgonine 
in saliva with the excitation and emission wavelengths set at 258 and 413nm 
[50]. Although simple to use, SS-RPT has the disadvantage of a high background 
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signal from the filter paper substrate [51]. An easy to use street test could detect 
350 nM of morphine and its metabolites in urine using adsorption on cation-
exchange resin-coated plastic rods has been described by Henneberg et al., 
1984 [52]. No easy to use street test is currently available for quantitative 
detection of cocaine or its metabolites. Another technique, capillary zone 
electrophoresis, allows for the simultaneous determination of drugs without the 
need for chemical modification which is specifically used in the determination of 
cocaine and its metabolites in hair [53,54]. Capillary electrophoresis is a label-
free method that uses the intrinsic properties of cocaine for its detection in 
biological fluids with a detection limit of 2 µM [29]. 
Thin layer chromatography helps in simultaneous detection of the parent 
compound, cocaine, and its metabolites such as benzoylecgonine and 
cocaethylene along with other interfering drugs. The sensitivity of cocaine 
detection by thin layer chromatography (TLC) has been reported to be 3-5 µg/ml 
which is equivalent to 10-15 µM cocaine c [34]. Chromatographic techniques 
have their limitations in terms of sample separation, sample pre-concentration 
and isolation of the compound required for the sensitivity and selectivity of the 
assay. Not all drugs can be solvent extracted as is the case with morphine, which 
displays a poor solubility in both ether and chloroform. Derivatization, such as 
sialylation, acylation, or alkylation, is necessary for both the chromatography and 
electron ionization mass spectrometry techniques. These added procedures in 
sample preparation are not only time consuming but may also require 
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professional expertise that can substantially add to the overall cost of the assay. 
Also, urine and oral fluids contain hydrophilic and hydrophobic components such 
as inorganic salts, proteins, enzymes, and carbohydrates that interfere in 
detection of the compound of interest. Techniques such as high performance thin 
layer chromatography (HP-TLC) [55], high performance liquid chromatography 
(HPLC) and high pressure liquid chromatography with ultra violet detector 
(HPLC-UV) [56-58],  HPLC with fluorescence detection (HPLC-FL) [59] and, 
HPLC with mass spectrometry (HPL-MS) provide much more sensitivity, 
specificity and separation for better qualitative and quantitative analysis of 
cocaine and its metabolites in hair, blood and urine [60,61]. HPLC-UV can detect 
cocaine in concentration range of 0.1-10 µg/ml or 0.3-30 µM range [62,63]. The 
HPLC-FL has a detection limit of 1 ng/ml or 3 nM for cocaine and its metabolites 
[62,64]. HPLC with time of flight MS (HPLC-TOF-MS) can also be used for very 
sensitive detection of cocaine and its metabolites. However, the use of HPLC-
TOF-MS is limited by the extreme cost of equipment and also because of the 
requirement of qualified personnel for its operation [65-68]. Ultra performance 
liquid chromatograph-MS (UPLC-MS) has been successfully used for detection 
of cocaine and its metabolites in different matrices, such as urine and hair, with 
decreased overall run times [39,69,70]. Approaches like matrix-assisted laser 
desorption/ionization-time of flight (MALDI-TOF) are considered impractical for 
the detection of cocaine or its metabolites because they require high 
concentrations of analyte and the development of complex spectral fingerprints 
for the target of interest [71]. Fernandez et al., 2005 evaluated the cocaine, 
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benzoylecgonine and cocaethylene in 23 fatal intoxication cases using high 
performance liquid chromatography with diode array detection (HPLC-DAD). The 
authors reported the detection of benzoylecgonine, cocaine and cocaethylene in 
urine at mean concentrations of  588, 83 and 14 µM respectively [72]. 
2.2.3 Immunoassays for the detection of cocaine and metabolites 
Immunoassays for quantitative and qualitative analysis of controlled 
substances mostly involve enzyme multiplied immunoassay (EMIT), 
haemagglutination inhibiton (HI) assay, fluorescence polarization immunoassay 
(FPIA) and radiommunoassay (RIA). Using these assays, the limit of detection 
for morphine using HI is 20-30 ng/ml. The advantage of the fluorescence 
polarization immunoassay is that it does not require sample preparation and is a 
specific and sensitive technique suitable for analysis of analytes of interest in 
whole blood. It is used as the method of choice for detection of cocaine and 
benzoylecgonine in meconium with detection limits of 600 ng/gm. In a study on 
29 patients presented to the emergency department of the Chicago Medical 
Center, Williams et al., 200 reported the urinary concentration in the range of 
13.2 nM-132.3 µM, 0.4-11.6 mM, and 0.2-3.3 mM for cocaine, benzoylecgonine 
and ecgonine methyl ester, respectively. In the 29 patients tested, 
benzoylecgonine was detected in 100% of the patients, while cocaine and 
ecgonine methyl ester was detected in 93% of the patients [73].  
Radiommunoassays do not require sample preparation and most closely 
match the sensitivity and specificity of GC-MS for detection of cocaine, 
12 
 
 
benzoylecgonine and ecgonine methyl ester in sweat and urine.  The RIA has a 
limit of 0.1 µg/ml, which is equivalent to 0.3 µM for cocaine detection [34]. 
Radioimmunoassays have shown to be sensitive at very low concentrations for 
digitoxin, dexamethasone, insulin, gentamycin, tobramycin, and drugs of abuse 
such as morphine, barbiturates, cocaine, amphetamines and methaqualone. As 
with other immunoassays, the reagents for RI are expensive and special 
technical skills for the conduct of these assays are required. Also reported are 
latex agglutination inhibition and immunochromatographic assay with detection 
limits of approximately 1 µM for cocaine [22]. Enzyme linked immunosorbent 
assay (ELISA) has proven to be time consuming and expensive for use in 
detection of small molecules. The generation of antibody for small molecules like 
cocaine or its metabolites has proven difficult for such assays. The ELISA owing 
to its higher costs plays a limited role in the detection of cocaine or its 
metabolites in urine. Also, the sensitivity of the ELISA is affected if antimicrobial 
agents are present in the urine [45]. The sensitivity of the EMIT assay for cocaine 
is approximately 3 µM and this assay exhibits cross reactivity with ecgonine 
which is a common metabolite found along with ergot compounds and 
prescription drugs like Methergine®. The cross reactivity is also seen with 
morphine and other opiates. The urinary metabolites of nonsteroidal anti-
inflammatory drugs (NSAIDS) have been reported to interfere with the antibodies 
used in the EMIT assay rendering the assay non functional [46].  
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Immunoassay cannot detect more than one analyte per assay and 
multiple assays have to be run simultaneously to detect multi analytes [71]. Most 
of the immunoassays detect the major metabolite of cocaine i.e. 
benzoylecgonine. The immunoassays can detect 300 ng/ml whereas the 
confirmatory test with GC/MS can detect 1 ng/ml of benzoylcocaine in both urine 
and blood. The haemeagglutination inhibition assays have been developed for 
cocaine metabolites in urine with sensitivity of 1 ng/ml [74]. Haemeagglutination 
inhibition assays, however, are significantly interfered with by non-specific 
hemagglutinins and hemagglutinin inhibitors [75]. Immunoassays are also 
sensitive to the presence of bacteria that can often be problem for urine samples. 
These samples need to be purified before analysis which adds to the time 
required for analyte detection in such assays. 
2.3. Introduction to Aptamers 
Aptamers are single stranded RNA or DNA molecules that bind to their 
target molecules with high specificity and affinity [76]. The word aptamer is 
derived from the Latin word 'aptus' which means ‘to fit’ [77,78]. Specific aptamer-
ligand association is a result of molecular interactions, specific hydrogen binding, 
electrostatic interactions, van der Waals forces, and complementarity of 
molecular shape [79]. Aptamer ligands may include small molecules [80,81], 
drugs [82], proteins or cells [83]. Aptamers are generated from combinatorial 
libraries of synthetically derived nucleic acids by the process called SELEX 
(Systematic Evolution of Ligands by EXponential Enrichment) that involves 
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reiterative adsorption, selection and amplification [78,84] and which results in the 
generation of high affinity and high specificity nucleic acid sequences. Aptamers 
are very specific and can differentiate target analytes and non-specific molecules 
based on their subtle structural differences such as the presence or absence of a 
methyl or hydroxyl group.  Aptamers are also enantioselective in nature, for 
example, the arginine aptamer has been reported to be 12000 time more 
selective for L-arginine then D-arginine [85]. Aptamers have also been reported 
to be functional in complex matrices, such as blood serum [86]. Rapid detection 
of analyte in aptamer based assays obviate the need of nuclease resistant 
aptamers.  The cocaine aptamer is reported to be stable for nuclease 
degradation in serum with even a brief duration of exposure [87]. The authors, 
however, did not quantify the duration of exposure. The selection of toxicant 
specific aptamers will revolutionize the way we look at diagnostics and treatment 
in the field of toxicology. Aptamers can be put to a wide range of applications 
including clinical diagnosis of various diseases and disease susceptibility, 
development of personalized medicines, forensic medicine, diagnosis of 
biowarfare agents, biopharmaceutical industry, drug discovery, molecular 
toxicology, pharmacogenomics, detection of microbial contamination, 
biopharmaceutical manufacturing, public health, and molecular epidemiology.  
2.4 The process of SELEX 
Rapid screening techniques using aptamers have become possible due to 
high affinity aptamers against the analyte of choice on the chosen conditions of 
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binding. Aptamers are generated from combinatorial libraries of synthetic nucleic 
acids by exponential enrichment through the reiterative adsorption, selection and 
amplification process called SELEX [77,78,84]. The first step in SELEX involves 
the generation of the very large pool of approximately 1012-1015 oligonucleotides 
of random sequence. The process allows for generation and optimization of 
nucleic acid sequences that can bind to non-nucleic acid targets such as 
cofactors, peptides, proteins, amino acids, saccharides and other lipids with high 
sensitivity and specificity [88-91]. The SELEX process involves three steps: 
selection of ligand sequence that binds to the target molecule, partitioning of 
aptamers from non-binding species through affinity methods and finally the 
amplification of bound aptamers. Choosing the initial pool of SELEX involves the 
consideration of factors such as type of randomization, length of the random 
sequence and utility of the constant regions. The starting pool for a successful 
SELEX is a library containing molecules in the range of 109 to 1013 
oligonucleotides. Aptamers are selected under specific buffer conditions and 
temperatures that are consistent with the conditions anticipated for the end use 
of aptamer. SELEX starts with a low ratio of nucleic acid to target molecule of 1 
or more. After incubation for binding, the RNA/DNA aptamer-target complex is 
partitioned form non binders by such means as nitrocellulose filter partitioning 
and the selected oligonucleotides are then amplified for the next cycle. 
Depending upon the degree of stringency of the selection conditions, the 
selection process is generally repeated for 8-15 rounds and then the selected 
oligonucleotide pool is cloned, sequenced and putative aptamers are identified 
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and tested. The chosen aptamer is then optimized for binding affinity. SELEX 
obviates the need of animal hosts and has comparative advantage in terms of 
time, labor and purification when compared to the generation of antibodies [92].  
Thus far, the in vitro selection of aptamers has proved to be an extremely 
facile and robust method for generating receptors for a variety of targets. 
Aptamers can now be thought of as universal receptors similarly to the way that 
antibodies have previously proved to be. However, unlike antibodies, aptamers 
can be converted into readily synthesized diagnostic reagents that immediately 
report interactions with cognate ligands in solution. The development of high-
throughput methods for the selection of signaling aptamers is potentiating the 
development of sensor arrays that can detect large numbers of non-nucleic acid 
analytes, such as the mycotoxins.  The adaptation of selected nucleic acid-
binding species (aptamers) to function as biosensors would potentiate numerous 
diagnostic applications. The incorporation of chemically modified bases into 
aptamers drastically improves their stabilities and potentially renders them 
suitable for use in homogeneous assays in different samples. 
Aptamers can be linked to fluorophores post selection for the 
Fluorescence Resonance Energy Transfer (FRET)-based assays. Covalent 
linking of fluorophores to the aptamers is not only costly and time consuming but 
such modifications may also influence the aptamer structure and affect ligand 
binding.  Incorporation of fluorophores have been reported to affect the binding 
either through steric hindrance or by affecting the folding properties of the 
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aptamers. To avoid the effects of post-selection modification, the aptamers can 
instead be selected for their targets with the incorporation of the fluorescence 
tags in the starting oligonucleotide pool in the SELEX process [93]. 
2.5 Advantage of use of aptamers over antibodies in detection assays 
Aptamers have been reported to be used as therapeutic [94], diagnostic 
[95,96] and analytical [97] tools. Over the years aptamers have become a robust 
alternative to antibodies for detection of small molecules [98]. Antibodies have 
limited shelf life, lack structural robustness in conditions of varying temperatures 
and humidity [99] and also labeling of the antibody can cause loss of affinity 
[100]. Aptamers offer a promising alternative to antibodies to be used as 
biocomponents in aptasensors. They have selectivity, specificity and affinity 
either equal or greater then antibodies [101]. Other advantages include their easy 
in vitro generation without the need of a host system, their ease of modification, 
retention of functionality over a range of temperatures, lower variability amongst 
different production batches, relatively smaller size compared to antibodies, lack 
of immunogenicity, ease of chemical modifications, and greater stability 
[99,102,103]. Aptamers can be labeled with radioactive, fluorescent or other 
reporters and have the capability to replace antibodies in several assays 
including ELISA [104], flow cytometry [105], affinity chromatography [106,107], 
affinity probe capillary electrophoresis [108], aptamer arrays [109] and high 
throughput screening [107]. Aptamers can be easily synthesized and chemically 
modified at terminal sites or through bases that are not involved in binding 
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thereby facilitating their attachment to stationary surfaces without loss of affinity 
[110]. This advantage of labeling of aptamers allows for aptamer conjugation with 
nano-material composed devices such as microcantilevers [111,112].  Aptamers 
remain stable upon long term storage and transport and have the advantage of 
reversible denaturation allowing them to be denatured and reused many times 
without the loss of functionality. Aptamer binding to its ligand is the outcome of 
simple and stable secondary structure interactions within the nucleic acid that 
provide the same options for ligand interactions as exist in antibodies [113]. 
Aptamers also have the advantage of control over their kinetic parameters such 
as ‘on’ and ‘off’ rates, whereas antibodies cannot readily be modified to alter 
these characteristics [87]. Antibodies cannot be generated for highly toxic 
substances in vivo whereas aptamers can be generated for such substance 
under in vitro conditions. Aptamers can also be generated against toxins and 
small molecules that do not elicit an immune response that is necessary for 
generation of antibodies. Aptamers also allow the flexibility to be generated 
against specific region of the target. Such region-specific targeting is not possible 
to specify in the generation of antibodies although, selection of antibodies to 
epitopes can be achieved when multiple monoclonal antibodies are obtained that 
recognize a single antigen. Aptamers can be generated to identify their ligands in 
non-physiological conditions such as low pH or in the presence of solvents. 
Aptamers also have an advantage over antibodies in sandwich assays that utilize 
small molecules such as toxins, drugs and hormones where the primary aptamer 
could bind to hapten target and labeled aptamer can then bind to the aptamer-
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hapten complex [82].  Aptamers lack immunogenicity and therefore can also be 
applied to therapeutics [114].  
2.6 Aptamer structure and specificity 
 Nucleic acid aptamers [91,115,116] often undergo a significant change in 
the conformation and dynamics upon ligand binding and display high degrees of 
ligand recognition and distinction amongst closely related targets [84,117]. 
Aptamers bind to their ligands through a combination of well-defined structural 
motifs [118].  Three-dimensional structural analyses of aptamer-ligand 
complexes have provided valuable insights into molecular recognition 
mechanisms by nucleic acids. Some aptamers are predominantly unstructured in 
solution and fold upon associating with the cognate ligands. Ligands form the 
intrinsic part of aptamer architecture and contribute to the stability of the aptamer. 
Aptamers structures commonly include non-canonical base pairs. Nucleotides 
that are not conserved in the aptamer and which do not directly interact with the 
ligand may play a role in providing the overall stability to the aptamer. Bases that 
do not form hydrogen bonds within the loop region of the aptamer may be 
involved in intra- and/or inter molecular stacking interactions [119]. Insights from 
structural analysis and computational modeling that result in a better 
understanding of the aptamer-ligand complex are expected to be very helpful for 
developing more effective aptamer based biosensors or for structure-based drug 
design strategies with relevance to therapeutic intervention, diagnosis and drug 
remediation [120]. 
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 Aptamers discriminate between closely related ligands, through van der 
Waals interactions, intermolecular hydrogen bond alignments, intercalation 
dependent cavity formation, shape and charge complementarity, encapsulative 
recognition, precise stacking of flat moieties and base stacking interactions [121]. 
Intermolecular hydrogen bonding alignments of hydroxyl, protonated and other 
motifs on the ligand have been reported with the base edges, sugar ring oxygen 
atoms and backbone phosphates of the polynucleotides [122]. The planar nature 
of nucleotide bases lead to spatial and energetically favorable stacking 
interactions in aptamer complexes that play an important role in aptamer-ligand 
complexes involving flat ligands such as AMP, theophylline, FMN etc. [123-126]. 
Intermolecular hydrogen bonds contributed by polar edges of multiple bases that 
surround the binding pocket and sandwich of the ligand between mismatch and 
regular base-pairs may also play a critical role in the aptamer ligand complex 
formation [127-129]. Examples of such aptamer-ligand interactions include the 
discrimination of the RNA ATP aptamer to bind to  AMP and other nucleoside 
triphosphates based on the RNA folding topology, stacking alignments and the 
intermolecular hydrogen bonding associated with molecular recognition 
[119,130]. Aminoglycosides are recognized by their respective aptamers through 
a combination of electrostatic interactions, hydrogen bonding involving the 
aminoglycosidic polar groups and shape complementarity [128,131-133]. The 
three-dimensional structures of aptamer complexes form highly optimized 
scaffolds for specific ligand recognition [134]. The enclosure of the ligand by the 
nucleic acid folding provides unique discriminatory intermolecular contacts that 
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result in aptamer specificity and affinity. A significant change in conformation and 
dynamics upon ligand binding has been reported for the theophylline aptamer, 
which has a dissociation constant of 100 nM for theophylline. This affinity is 
10,000-fold greater compared to that for caffeine, which differs from theophylline 
only by a methyl group at nitrogen atom N-7 [117].  
 Relative to the total number of aptamers discovered to date the structures 
of very few aptamers have been determined by either NMR spectroscopy or X-
ray crystallography [125,135,136]. Heteronuclear multidimensional nuclear 
magnetic resonance (NMR) methodologies have been effectively used to 
determine the solution structures of several aptamers. Solution structures of high 
affinity aptamers can be determined using NMR methodologies owing to their 
narrower NMR resonances resulting in easily interpretable NMR spectral 
parameters [120,137]. Fourmy et al. 1996 identified key positions on the 
paromomycin molecule that interact with the conserved regions of the RNA 
aptamer to form the aptamer-ligand complex [122]. The authors also reported  
several -OH and charged -NH2 groups on paramomycin that were responsible for 
the formation of intermolecular hydrogen bonds with the base edges, sugar ring 
oxygen atoms and backbone phosphates. These interactions are responsible for 
anchoring the aminoglycoside antibiotic in the binding pocket of the aptamer. 
Similar structural studies associated with RNA folding and recognition in the 
AMP-RNA aptamer complex have been extended by studies of the base pair 
kinetics of nucleotides using NMR proton exchange assays [138,139]. The 
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formation of a specific hydrogen bonds in the ligand binding pocket in addition to 
stacking has been reported for AMP-RNA [140] and AMP-DNA [141] aptamer 
complexes. Yang et al. 1996, in their two-dimensional nuclear magnetic 
resonance spectroscopy studies reported the coplanar alignment of arginine 
motifs with cytosine for the formation of two hydrogen bonds with the ligand. 
Hydrogen bonding was also reported to be essential for the specificity of  
aptamers that bind arginine and citrulline [127]. The NMR-based structural 
restraint, if available for the aptamer, can also be used for molecular dynamics 
calculations to determine the recognition interfaces in the aptamer-ligand 
complex. 
 Several aptamer structures have been deciphered through NMR studies 
[130]. Reliable determination of hydrogen bonds using NMR spectroscopy is 
hindered in the absence of sufficient NOE (Nuclear Overhauser Effect) restraints 
to adequately define the location of certain groups. There are also  uncertainties 
for the molecular weight limits of aptamer-ligand complexes for which NMR 
structures can be obtained [90,119]. Complementary to NMR and X-ray 
crystallographic structural data [118,142,143], several alternative strategies have 
been employed to understand aptamer-ligand interactions. Binding studies of the 
theophylline aptamer were done with compounds chemically related to 
theophylline such as xanthine, caffeine, etc.  It was hypothesized that the N-7 
hydrogen of theophylline forms a hydrogen bond with an acceptor in the 
theophylline aptamer binding pocket. Therefore, it was proposed that the reduced 
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binding to caffeine,  with a  N-7 methyl, could be because of steric interference in 
the binding pocket that prevented the inclusion of the methyl group on caffeine or 
the inability of caffeine to form a critical hydrogen bond in the binding pocket of 
the aptamer [117]. Hermann and Patel, 2000 attributed the selectivity of the 
theophylline aptamer for theophylline to a combination of stacking that stabilizes 
theophylline within the aptamer fold, and intermolecular hydrogen-bonding 
interactions [121]. Selectivity of the theophylline aptamer may also result from a 
pseudo base pair between a cytosine in the aptamer and the purine-like 
theophylline. Formation of the pseudo base pair formation with caffeine is 
inhibited by the presence of methyl group at N-7 which renders the theophylline 
aptamer specific for theophylline compared to caffeine [144].  
 Specificity of the AMP aptamer was also attributed to a specific hydrogen 
bonding scheme that involves pseudo base pair formation with the ligand 
[118,143]. In a different study involving the thrombin aptamer, base pair 
substitutions were done to determine the specific bases that interact with 
thrombin in the aptamer [145]. A similar aptamer-ligand recognition based on 
hydrogen binding and stacking interactions  was reported for the flavin 
mononucleotide-RNA aptamer complex  [142]. Yang et al. 1996 also reported the 
specific binding of the  arginine and citrulline to their respective aptamers to be 
dependent upon hydrogen bonds between the amino acids and functional groups 
in the aptamer nucleobases [127].  
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2.7. Aptasensors for cocaine 
 Oligonucleotides have long been considered as functional biopolymers for 
the storage of genetic information. The ability of nucleic acids to bind to specific 
ligands and their subsequent application as tools in biosensing takes them 
beyond their standard realm of storage and transmittance of genetic information. 
The development of several important bio-analytical methods has been based on 
the resulting conformational changes that occur in aptamers on their interaction 
with ligand. Progress in the development of oligonucleotide-based sensing 
technology and its subsequent use in diagnostics, bioanalysis, therapeutics, 
environmental monitoring, clinical toxicology, drug discovery and forensics [146-
154] is contingent upon the development of new rapid, accurate,  cost-effective 
and easy to use methods. There are several molecules used in rational design of 
biosensors that include proteins and oligonucleotides [155-159]. Amongst all the 
molecules currently in use, oligonucleotides are the easiest to engineer due to 
advances in the molecular and computational biology techniques. Aptamers have 
now been extensively reported to have been used in analytical chemistry 
applications such as in the form of immobilized sensors or in homogeneous 
assays [160]. The ability to synthesize and manipulate aptamers through rational 
design has been among the general goals of analytical biochemistry. Aptamer-
based sensors have several  advantages, which include high stability, low cost, 
and ease of synthesis and modification. However, most the current aptasensors 
for cocaine detection are not cost effective either due to the cost of the 
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biosensing platforms or due to the modifications/labeling of the aptamer itself.  In 
the last few years various aptamer based signaling strategies have been 
successfully tailored to transduce the structural change upon aptamer ligand 
interaction into physically detectable fluorescence signals in analytically 
challenging and complex matrices [161].  
 Aptamers have been engineered  for a broad range of targets ranging  
from 100 to 10,000 Da such as a small molecular weight ethanolamine [98] or 
high molecular weight proteins targets such as thrombin [135]. Of particular 
importance has been the development of aptamers for detection of small 
molecules that otherwise would need the development of antibodies. 
Development of such antibodies is not only capital intensive but also antibodies 
are difficult to be generate against small molecules due to the challenges 
associated in eliciting an immune response. Compared to antibodies, aptamers 
show comparable or better affinity for the targets with the dissociation constants 
in the picomolar to nanomolar range for proteins and nanomolar to micromolar  
range for small molecules [161].  
A biosensor is a device/detection system that combines biological 
recognition with a physical transducer that reacts to mass, charge, light, 
pressure, temperature or humidity [87,162,163] [164]. The sensor contains the 
components of target recognition element and signal transduction element [165]. 
There have been a number of reports of aptasensors using the currently 
available cocaine aptamer. Stojanovic et al, 2001 used fluorescein as fluorophore 
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and dabcyl as the quencher in a molecular beacon design based on their 
predicted secondary structure of the cocaine aptamer to detect cocaine and 
cocaine hydrolases in serum samples [30]. In the absence of cocaine the two 
ends of the aptamer were proposed to be separated resulting in lower quenching 
of the fluorophor. However, in the presence of cocaine a three way junction was 
predicted to form to bring the fluorophor and the quencher close together leading 
to almost 50% quenching of fluorescence signal. This assay could detect 10 µM 
cocaine in serum samples. Using this principal of fluorescence quenching the 
same authors later reported the detection of cocaine in the range of 10-1000 µM 
using a split cocaine aptamer that comes together in the presence of cocaine 
resulting in the signal being quenched by 40% [166]. The authors also reported 
displacement of a cyanine dye from the aptamer binding pocket to detect 20 µM 
of cocaine in solution [167].  
A colorimetric sensor based on analyte-induced disassembly of gold 
nanoparticle aggregates has been reported as a means to detect cocaine [168-
172] and other ligands such as ampicillin [173,174]. Aptamer based molecular 
recognition results in quantitative detection of molecular events using simple 
absorption spectroscopy when the aptamers are attached to gold nanoparticles. 
The split cocaine aptamer can be used to detect cocaine in the low micro-molar 
range based on reassembly of the cocaine aptamer leading to the aggregation of 
attached gold nanoparticles [170]. Detection of cocaine in such an optical assay 
is based on size and distance responsive surface plasmon resonance (SPR) 
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properties of gold nanoparticles [175]. Aptasensors also have the potential of 
simultaneous multi analyte detection. Simultaneous but non-specific detection of 
adenosine and cocaine, in the same analyte mixture, with a sensitivity of 1 mM 
has been shown to be possible in ligand dependent aggregation of gold 
nanoparticles [176].  Using the specific signals of quantum dot emission 
technology, 120 µM cocaine could be detected [165]. However, colorimetric 
methods using gold nanoparticles have been reported to have unstable signals  
due to instability in the aggregation and dispersion of gold nanoparticles particles 
[175]. 
Adaption of antibody-based lateral flow technology for detection in 
biological samples, such as used in pregnancy kits, was demonstrated using the 
cocaine aptamer with a detection limit of 10 µM [177]. Lateral flow technology 
takes advantage of the physical size difference of the stationary nanoparticle 
phase and the mobile phase and integrates analyte binding, separation and 
detection on a single platform. For example, a fluorescence aptamer-based 
detection in which a fragment displaced by the binding of analyte was used to 
open a molecular beacon has a reported detection limit of 5 µM cocaine [178]. 
 The application of aptasensors for electrochemical detection based on a 
structural change has provided a sensitive platform for the detection of cocaine 
[179-187]. The cocaine aptamer with methylene blue (MB) as an electroactive 
label was used to detect cocaine in different biological fluids such as blood, 
serum, saliva and contaminated samples containing the cocaine masking agents. 
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The ‘signal on’ assay can detect 10-500 µM cocaine and 0.5 nM of thrombin with 
a signal increase of about 16%. In this assay the cocaine aptamer was attached 
to a gold electrode and the structural change following cocaine binding brought 
the MB label close to the surface leading to generation of current [188]. Using the 
same principle of structural change attributed to the binding of cocaine to the 
cocaine aptamer an electrogenerated chemiluminescence aptamer-based 
biosensor was reported for the determination of cocaine with a detection limit of 1 
nM [189]. A detection system for cocaine should be preferably “signal on” rather 
than “signal off” as the latter are more susceptible to false positives due to sensor 
degradation [190]. Recently, an optical aptamer sensor, based on minor groove 
binder based energy transfer, was utilized for cocaine detection. The authors 
utilized fluorescence of the dye Hoechst 33342 for the quantitative analysis of 
cocaine via the conformational transformation of the cocaine aptamer upon 
cocaine binding [191]. 
2.8 Fluorescence based aptasensors  
 Fluorescence is the word derived from the mineral fluorspar (Calcium 
fluoride). Fluorescence is short lived type of luminescence created by 
electromagnetic excitation. The wavelength of fluorescent light is always greater 
than that of the exciting radiation (Stokes Law/Stokes shift) and the length of time 
between absorption and emission is 10-9 to 10-8 seconds. The structural flexibility 
and the frequent post-target binding tertiary structural rearrangement make the 
aptamers suitable for fluorescence based detection systems. Aptamers 
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spontaneously fold into secondary and tertiary structural domains containing 
stem-loop and internal loops [79,121,192,193]. A few of these oligonucleotides 
interact with a specific target with high affinity and specificity through van der 
Waals contacts, hydrogen bonding and base stacking interactions [85]. Several 
schemes have been adopted to transform aptamers into “signaling aptamers”, 
which are mainly based on reporting the target presence by real-time 
fluorescence signaling. One strategy to modify aptamers with fluorophores and to 
design a real-time signaling aptamer, is the attachment of a fluorophore at a 
specific position of an aptamer that can undergo a conformational change 
induced by its binding the target. If an aptamer is modified by introducing a 
fluorescent moiety into the ligand-binding site, then significant changes in 
fluorescence on binding can be detected [194]. In the Fluorescence Resonance 
Energy Transfer (FRET) the fluorophores having characteristic peak absorbance 
and peak emission are selected. Acceptance of donor energy in a FRET pair 
depends upon the compatibility and proximity of the two end labeled 
fluorophores. Energy generally emitted from a fluorophore is in the form of light 
but if the energy is lost through heat dissipation then quenching is observed. 
Aptamers that bind small molecules have been shown to undergo conformational 
changes upon interactions with their cognate ligands. It is reasonable that, if a 
fluorophore is introduced in an aptamer in a region known to undergo 
conformational change, the binding event might lead to a change in fluorescence 
intensity even when tested in the presence of complex mixtures. Due to the ease 
labeling nucleic acids in specific locations with fluorescence, aptamers are also 
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being extensively used in biosensor technologies including in proteomic and 
metabolomic applications.  
 Following their selection using the SELEX process, individual aptamers 
can be screened for their ability to signal the presence of a cognate ligand.  Most 
fluorescence-based assays involve the post-selection modification of aptamers 
[195], however, the process of SELEX also enables the direct selection of 
aptamers for fluorescence based assays [196]. Most aptamer based sensors rely 
on a conformational change of the aptamer upon analyte binding. However, Ito et 
al. 1998 reported a negligible effect of thyroxine (T4) on the structural 
characteristics of the T4 aptamer, but could still apply the aptamer in 
bioanalytical applications such as competition assays with a  fluorescent 
derivative of the target [197]. Recently a fluorescent strip sensor based on 
aptamer-quantum dot technology was developed to quantify ochratoxin A (OTA), 
which can detect ng/ml levels of OTA [153].  Knowledge of the position to label 
aptamers for a good signal can be limited by a lack of certainty of the target 
binding sites and the conformational changes associated with the aptamer upon 
ligand binding. Precise underlying structural details of many aptamers are not 
available. In these cases, molecular simulation can be used to predict 
appropriate sites for modification. Preferably the signaling aptamers should be 
easy to synthesize with a single modification such as the attachment of the 
signaling dye. Aptamers should be able to perform in different buffer 
environments and biological fluids. Aptamers often undergo target-dependent 
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induced fit or conformational change in the presence of their cognate ligands 
[198]. A dye attached to an appropriate location in the aptamer can often 
undergo a ligand-dependent fluorescence change due to alterations in its local 
environment.  
 Most reported studies on aptasensors have been conducted in controlled 
in vitro environments with very few reports validating the use of aptasensors in 
biological fluids. For the aptamers to be clinically relevant, as biosensors in 
biomedical research, diagnosis and forensics, they need to be validated in 
complex biological fluids such as urine, blood, saliva and serum [199,200]. The 
most commonly collected biological samples include urine and serum which can 
affect the sensitivity of the analytical signal due to aptamer ligand binding [201]. 
Both urine and serum absorb approximately 30% of the light at 492 nm, exhibit 
high background fluorescence and have variable ionic strengths [202]. Urine in 
particular, contains a number of natural fluorophores that include 5-hydroxy-3 
acetic acid (5-HIAA), indoxyl sulphate (urine indican), serotonin (5-HT), 
vanillylmandelic acid (VMA) and the homovanillic (HVA) acids, which respectively 
have the λex/λem of 276/341, 276/386, 277/341, 277/318, and 279/315 nm 
[203,204]. Dubayova et al, 2003, in their diagnostic studies on human urine 
reported that the fluorescent peak of 324/420nm is due to the additive effect of 
several fluorescent compounds, such as 4-pyridoxic acid, 3-hydroxyxynthranilic 
acid, xanthine, present in normal human subjects [205]. 
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 Even though aptamers retain their functions when exposed to the harsh 
environmental conditions [198,206], the performance of some  aptamer sensors 
has been reported to substantially decreased in biological fluids [146]. Therefore, 
for aptamers to have more practical relevance it is important to optimize them for 
activity in biological fluids. In the case of RNA aptamers the degradation of RNA 
molecules by the endogenous ribonucleases found in serum limits their use to 
only physiological buffer solutions unless they have been modified for RNase 
resistance. Merion and Weeks, 2005 reported a fluorescent assay for the DNA 
aptamer based detection of AMP in 50% unmanipulated human urine or 25% 
fetal bovine serum [202]. The authors reported identical binding affinities of the 
aptamer for AMP in urine and serum compared to their experiments in buffer 
solution containing 50 mM Hepes, pH 7.5, 100 mM NaCl, and 10 mM MgCl2. 
Jiang et al., 2004 reported the use of a label-free DNA and RNA aptamers for the 
luminescence emission based homogeneous protein detection [207] that 
depended upon a target induced conformational change in the aptamer structure.  
The protein could be detected in this assay down to the limit of 1 nM in both the 
physiological buffer and 1% serum sample.  
 The aptamers can be labeled with malachite green [208] that change their 
fluorescence properties upon aptamer binding or fluorophores such as  
fluorescein [209], which has strong intrinsic fluorescence. These fluorophores are 
strategically attached to the aptamer for the aptamer based fluorescence 
quenching [30,210,211] or dequenching [195,212,213] assays. By this means, a 
method was developed to detect human thrombin by an aptamer based optical 
33 
 
 
sensor based on the structural change of the anti-thrombin aptamer. The 
determination of the binding of the aptamer to thrombin was specifically 
transduced into the optical readout signal [214]. Patel et al. 2011 reported the 
fluorescence based adenosine sensor which showed a target induced decrease 
in the fluorescent signal in the nM to µM range [215].  
Another approach to detect the binding event between aptamer and ligand 
was to use a dye (diethylthiotricarbocyanine iodide) displacement assay for the 
colorimetric detection of cocaine [167]. The addition of cocaine resulted in the 
displacement of the dye, which was pre-incubated with the aptamer, causing 
attenuation of absorbance. The decrease in absorbance of the dye was 
proportional to the cocaine concentration. In another study, fluorescence 
enhancement was used to detect the presence of K+  using the dye OliGreen 
(OG) which resulted in more than a thousand fold increase in the fluorescence 
intensity upon DNA binding [213].  
 Based on the tertiary structures of aptamer–ligand complexes, it is 
feasible to modulate their function chemically. The split aptamer approach was 
used to detect cocaine with an electrochemiluminescence (ECL) sandwich 
biosensor. The design was based on splitting the aptamer into two dissociated 
fragments which associated in the presence of cocaine [146]. The split cocaine 
aptamer has been reported with the formation of pyrene excimer upon assembly 
of the two dissociated aptamer pieces in the presence of cocaine [216]. The 
cocaine induced self assembly in this assay was monitored using UV 
spectroscopy. In another approach Nutiu and Li, 2004 described a structure 
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switching fluorescence dequenching mechanism for the detection ATP and 
thrombin based on the use of a fluorophore-labelled DNA aptamer and of a small 
complementary oligonucleotide (QDNA) modified with fluorescence quencher. 
Two different, RNA and DNA anti-adenosine signaling aptamers with fluorescent 
reporters were developed for the detection of adenosine in solution [217]. 
Electrochemical techniques using redox-active aptamers have a signal output 
with either the increase or inhibition of the electron transfer between the redox-
active components in the assay [218,219].  
 Aptamers can be directly modified with fluorophores and the 
conformational changes of the aptamers can be detected by fluorescence 
resonance energy transfer (FRET) based assays. The aptamer ligand interaction 
can be measured depending upon the increase (signal-on mode) or decrease 
(signal-off mode) of the FRET signal. Stojanovic et al. 2001 reported the 
fluorescence quenching of the FRET signal upon anti-cocaine aptamer binding to 
cocaine [30]. The aptamer was end-labeled with a fluorophore and a quencher 
and cocaine binding by the aptamer resulted in fluorescence quenching due to 
close proximity of the FRET pair. This assay could detect cocaine in the µM 
range with high specificity compared to cocaine metabolites such as 
benzoylecgonine. 
 Another interesting approach has been the use of molecular beacons. 
Molecular beacons [220] also known as aptamer beacons [221] are single-
stranded oligonucleotide hybridization probes that form a stem-and-loop 
structure. The loop contains a probe sequence that is complementary to a target 
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sequence, and the stem is formed by the annealing of complementary arm 
sequences that are located on either side of the probe sequence. A fluorophore 
is covalently linked to the end of one arm and a quencher is covalently linked to 
the end of the other arm. Molecular beacons do not fluoresce when they are free 
in solution [222]. However, when they hybridize to a nucleic acid strand 
containing a target sequence they undergo a conformational change that enables 
them to fluoresce brightly, a property used in signal transduction [223] through 
fluorescence-signaling using Fluorescence Resonance Energy Transfer (FRET) 
[224]. In the absence of targets, the probe is dark, because the stem places the 
fluorophore close to the nonfluorescent quencher that they transiently share 
electrons, eliminating the ability of the fluorophore to fluoresce. When the probe 
encounters a target molecule, it forms a probe-target hybrid that is longer and 
more stable than the stem hybrid. The rigidity and length of the probe-target 
hybrid precludes the simultaneous existence of the stem hybrid. Consequently, 
the molecular beacon undergoes a spontaneous conformational reorganization 
that forces the stem hybrid to dissociate and the fluorophore and the quencher to 
move away from each other, restoring fluorescence. Aptamer beacons are thus 
ideal probes for use in diagnostic assays designed for genetic screening, SNP 
detection, amino acid recognition [85] and pharmacogenetic applications. 
Molecular beacons have three key properties that enable the design of new and 
powerful diagnostic assays: 1) they only fluoresce when bound to their targets, 2) 
they can be labeled with a fluorophore of any desired color, and 3) they are 
extremely specific so that they easily discriminate single-nucleotide 
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polymorphisms [225]. Approaches such as detection of thrombin using the anti-
thrombin aptamer manipulating the loop of the molecular beacon have also been 
described [221]. The molecular beacon approach is limited to aptamers that 
undergo large changes in their structures upon binding to their targets. As for all 
FRET-output constructs used with biological systems, molecular beacons also 
have some shortcomings, which include their susceptibility to degradation by 
intracellular enzymes or nucleases in the biological fluids that may lead to false 
positive or false negative results.  
Aptamers can undergo significant conformational changes upon target 
binding. Engineering of aptamer based sensor by taking advantage of target 
binding induced conformational change in the aptamer can be rationally used for 
fluorescence based biosensors. Allosteric regulation means that the binding of 
one molecule which will affect the binding affinity of the other. The optimization of 
such a sensor can lead to use of cocaine or its metabolites for rapid and simple 
detection technique. This sensor system has generalized applications and can be 
targeted to any ligand for which there is a corresponding aptamer. There are 
number of reports of allosterically regulated aptamers [226-229]. Cooperative 
interactions among different elements of allosteric aptamers are critical for its 
function. Under favorable conditions the energy can be transferred between two 
fluorescent molecules. This phenomenon of energy transfer is called 
Fluorescence resonance energy transfer (FRET) and depends upon the overlap 
of emission spectrum of the donor fluorophor with the absorption spectrum of the 
acceptor fluorophor, the orientation of the two fluorophor and the distance 
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between acceptor and donor molecules. FRET serves as a sensitive measure of 
fluorescence based on the structural change of the aptamer molecules. FRET 
can be effectively employed for allosterically regulated aptamers which are 
tandemly linked to each other such that the binding induced structural change in 
one aptamer leads to the structural changes in the linked aptamer/s [230]. There 
are a large number of well characterized fluorophores for the FRET based 
assays that provide signal in real time [231]. Fluorescence detection can be used 
for real time measurements in homogenous assays (without separation steps 
prior to reading the signal) in the field conditions with the use of highly sensitive 
portable fluorometers [146,232]. The high sensitivity of the fluorometer results in 
low consumption of materials for fluorescence based sensing.  
 Direct chemical labeling of the aptamer is useful approach for the 
development of analytical biosensors. Rational design of aptamers is important 
for the fluorescence based assays. Not all placements of fluorophores provide a 
large increase in signal. Yamana et. al. 2003 reported only a small change in 
fluorescent signal in aptamers labeled with fluorescein and acridine [233]. 
However, the same authors reported the successful use of bis-pyrene 
fluorophore that was incorporated in the design of signaling aptamer for detection 
of (ATP) in homogenous assays. The bis-pyrene fluorophore is sensitive to the 
local structural change caused by base-pairing and  nucleotide structural 
variations near its site of incorporation [234].  Oligonucleotide-based probes are 
divided into two main categories, which include the hybridization probes based 
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on the formation of complementary base-pairs and aptamer probes that involve 
the selective recognition of nonnucleic acid targets [235].  
With dsDNA as a template, a simple, sensitive, and cost effective aptamer 
sensor was developed using dsDNA-Cu NPs (copper nanoparticles) as 
fluorescent probe. [236]. Quantum dots (QD) fluorescence quenching has been 
used to detect thrombin. In this assay the fluorescence of the quantum dots was 
quenched by the structural alteration of the aptamer [237].   
 Most conventional aptamer based diagnostic assays rely on 
immobilization of either the aptamers or their ligands [238-241] as in the case of 
microcantilever  based aptasensors sensors [112].  Such assays are time 
consuming to develop and labor intensive, involving multiple immobilization or 
washing steps. In this context the development of homogeneous assay formats 
offer an easy to use and cheap alternative to detect analytes of interest. 
Examples of this approach include conjugating fluorescent dyes to specific target 
binding protein for the detection of maltose [242]. To develop a homogeneous 
assay, Jhaveri et al. 2000 designed signaling aptamers using the molecular 
simulations program  (Insight 2) by visualizing  and manipulating the structures of 
anti-ATP aptamers [217]. Fluorescent dyes were incorporated in proximity of the 
identified ATP binding residues and the change in fluoresce was evaluated in the 
presence of ATP in a homogenous assay. The extent of changes change in the 
fluorescence intensity varied depending upon the construct. The fluorescence 
changes varied from less than 5% to up to a range of 25-45% in the presence of 
1mM ATP. Successful rational design of oligonucleotide biosensors for FRET 
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output involve optimization of other factors such as photostability of the 
fluorophore, the pH and the buffer conditions, functionality in biological fluids, and 
the position of the fluorophore attachments [243,244]. The table below 
summarizes the discussed aptasensors for the detection of cocaine.  
Method Portable Detection 
limits 
Specificity Reference 
Fluorescence 
quenching 
assay 
Yes 10µM Cross reactivity with 
cocaine metabolites 
[30] 
Split aptamer 
assay 
Yes 10-1000µM Cross reactivity with 
cocaine metabolites 
[166] 
Displacement 
assay 
Yes 20µM Cross reactivity with 
cocaine metabolites 
[167] 
Optical assay 
involving 
disassembly of 
gold 
nanoparticles 
Yes Low 
micromolar 
Not tested  with 
cocaine metabolites  
[168-172] 
Optical assay 
involving 
assembly of 
gold 
nanoparticles 
Yes 1mM Not tested  with 
cocaine metabolites 
[176] 
Quantum dot 
emission 
Yes 120µM Not tested with 
cocaine metabolites 
[165] 
Antibody based 
lateral flow 
technology 
No 10µM Not tested for 
cocaine metabolites 
[177] 
Molecular 
beacon based 
fluorescence  
Yes 5µM Not tested for 
cocaine metabolites 
[178] 
Electrochemical 
detection 
No 10-500µM Not tested for 
cocaine metabolites 
[188] 
Electro-
chemiluminesce
nce  
No 1nM Not tested for 
cocaine metabolites 
[189] 
Microcantilever  No 5µM Not tested for 
cocaine metabolites 
[112] 
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2.9 2-Aminopurine  
 2-Aminopurine (2AP) is fluorescent analogue of adenine that has been 
widely used as a simple, and economical probe for the assessment of folding 
kinetics during ligand-induced secondary and tertiary nucleotide structural 
rearrangements [245-247]. In neutral solutions the peaks of the absorption and 
emission spectra are observed at approximately 303 and 370nm, respectively 
[248]. 2-aminopurine exists in a single protonation state in neutral solutions and 
its fluorescence properties mostly remain unchanged with pH variations [249]. 2-
Aminopurine can be substituted in strategic positions in DNA or RNA to act as 
site specific probe to monitor folding dynamics in order to decipher structural 
change of different segments within the nucleic acid [250,251]. 2AP fluorescence 
is strongly quenched in RNA [248] and DNA [246] when it interacts by stacking 
with the flanking bases [252,253]. Fluorescence changes due to aromatic base 
stacking have been reported to be due to changes in 2AP quantum yield, lifetime, 
and intensity decay kinetics [249]. Hydrogen bonding and solvation have 
negligible contribution to the fluorescence quenching of 2AP [248,252,254]. 
Other reports on the quenching of 2AP fluorescence in DNA are attributed to the 
distance-dependent electron transfer from 2AP to guanine [255].  
There are some unique advantages associated with the use of 2AP as a 
fluorescent probe. Two amino purine causes minimal structural perturbation of 
the DNA [256] in which it is incorporated and forms normal Watson-Crick base 
pair with thymine/uracil or with cytosine in a wobble configuration [257,258]. Also, 
the 2AP can be selectively excited in physiological solutions without interference 
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by the spectra of DNA, RNA or proteins because absorption for 2AP occurs at 
longer wavelengths than those of the nucleic acid bases and aromatic amino 
acids. Merino and Weeks reported the use of fluorescent markers to detect 
ligand induced structural changes in aptamers for which no significant structural 
information was available [202].  
Even when high resolution 3D structures are available these are single 
conformation ligand bound structures often obtained in the presence of high salt 
concentrations. Such information for 3D structures may not be relevant in 
predicting the sites for 2AP modifications for aptamers that are tested in solutions 
[259]. Aptamers have high tolerance for 2AP substitutions. Up to 10-15 percent 
of the bases have been reported to have been modified, even in the crucial and 
highly conserved tertiary structure regions, without affecting the overall folding of 
the nucleic acid [260]. The structure of the oligonucleotide remains unperturbed 
with the 2AP substitutions as long as the hydrogen bonding and stacking 
conformations are retained at the position of 2AP substitution [259]. The 
molecular interactions responsible for the fluorescence quenching mechanism of 
2-aminopurine have been "interpreted phenomenologically" [247,252].   
In the absence of NMR and crystallographic structural data for most 
aptamers the selection of proper 2AP labeling positions for the development of 
FRET based assay should be based on careful consideration of the secondary of 
the nucleic acids and sometimes on educated guesses. Also, the covalent linking 
of fluorophores to the aptamers may influence the aptamer structure and affect 
the ligand binding either through steric hindrance or by affecting the folding 
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properties of the aptamers. As more information on the tertiary structure of 
aptamers is made available, it may become increasingly easy to logically position 
the fluorescent tags such as 2AP in the aptamer sequence for the development 
of FRET based assays for the detection of toxic chemical species.  
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ABSTRACT 
 Nucleic acid aptamers have been utilized in many innovative analytical 
platforms with the goal of developing homogeneous assays for specific analytes. 
Their high specificities and adaptabilities to many sensor platforms make them 
excellent candidates for analyte sensors. The cocaine aptamer is reported as 
highly specific for cocaine and is seen as a good candidate for development as a 
probe for cocaine in many contexts.  Here we describe a detailed investigation of 
the cocaine aptamer and evaluate its suitability for detecting cocaine in biological 
samples by using isothermal titration calorimetry and fluorescence quenching of 
2-aminopurine (2AP) substituted cocaine aptamers.  We demonstrate that the 
aptamer’s specificity is broader than previously reported as it binds cocaine, 
norcocaine and cocaethylene. From our analysis of its interaction with a number 
of cocaine derivatives, we conclude that the aptamer binds all faces of the 
cocaine molecule.  The results from studies of the 2AP-substituted aptamers 
suggest that, contrary to the commonly presented view, the aptamer does not 
change substantially in structure upon binding cocaine.  The aptamer was found 
to bind cocaine in the presence of urine but with a decreasing affinity as the 
concentration of increased.  However, forensic application of this aptamer, 
especially for the detection of cocaine in biological fluids, is limited due to its 
broad specificity profile and its low binding affinity relative to the concentration of 
cocaine and metabolites generally found in biological fluids.  
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INTRODUCTION 
 Probe specificity plays a vital role in diagnostic and analytical methods. 
For this reason the reported high specificities of nucleic acid aptamers for their 
analytes and the adaptability of aptamers to a variety of analytical platforms has 
created great interest in these molecules as a new wave of highly selective 
probes for analytical chemistry.  For these reasons, the cocaine aptamer, initially 
reported to be highly specific for cocaine and not to recognize benzoyl ecognine 
or ecognine methyl ester, has been the focus of much investigation.1 Recently, 
the aptamer specificity has been extended to include norcocaine.2 However, a 
number of important cocaine metabolites have not been reported for their 
interaction with this aptamer including cocaethylene (benzoylecognine ethyl 
ester), which is an important metabolite formed when cocaine is consumed along 
with ethanol.3 
 Here we report a study of the specificity and ligand binding of three 
cocaine aptamer sequences1, 4 and several 2-amino purine substituted 
derivatives of one of them. We demonstrate that the aptamer is less specific than 
previously reported as it binds norcocaine and cocaethylene in addition to 
cocaine with approximately the same affinity for all three analytes.  We also used 
2AP-substituted aptamers to probe structural changes that might occur with 
cocaine binding and found no evidence for the large cocaine-driven structural 
changes that have been proposed for this aptamer. The affinities for cocaine of 
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these versions of the cocaine aptamer are in the micromolar range and decrease 
further in urine. Thus, we conclude that this aptamer is not a promising subject 
for the development of analytical assays for cocaine quantification.   
Materials and Methods 
Cocaine Aptamers  
 Cocaine aptamers (table of sequences in Supplemental Materials) were 
purchased from Integrated DNA Technologies (IDT), (Coralville, Iowa). All 
purchased oligonucleotides were prepared as standard desalted preparations. All 
2AP modified aptamers were characterized by λex = 303 nm and λem = 371 nm.  
Biological Samples 
Viral tested human pooled urine sample was obtained from 
Bioreclamation® Inc. The urine sample was certified to be Institutional Review 
Board (IRB) approved. The donors were verbally screened to be free of 
recreational drugs.  
Analytes 
 Cocaine (COC), norcocaine (NOR), cocaethylene (COE), 
benzolyecgonine (BZE), ecgonine methyl ester (EME), ecgonine ethyl ester 
(EEE), ecgonine (ECG), and anhydroecgonine methyl ester (AME) samples 
dissolved in acetonitrile or methanol  were purchased from Cerelliant (Round 
Rock, Texas). The analytes were isolated from acetonitrile or methanol by initially 
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diluting in deionized water, then dehydrating under vacuum during centrifugation 
(1400 rpm in Eppendorf Vacufuge) for two cycles, each for 45 min at 60oC. 
Synthesis protocols for the modified cocaine molecules (dihydroxy cocaine, 
cocaine-tertiary-N-Boc, cocaine-tertiary-N-biotin, amethyl cocaine and 
dithiomethyl cocaine) are described in detail in the Supplemental Materials.  
Isothermal Titration Calorimetry 
 Isothermal titration calorimetry (ITC) experiments were performed using a 
VP-ITC isothermal titration calorimeter (Microcal, Inc., Northhampton, MA). The 
cocaine in the syringe and the cocaine aptamer in the cell were dissolved in 
buffer A (20 mM Tris.HCl- pH 7.4, 140 mM NaCl, 5 mM KCl) with the addition of 
urine where indicated.  A detailed description of the ITC analysis is given in 
Supplemental Materials. 
Fluorescence Spectra Measurement 
 Fluorescent spectra were obtained using a fluorescence 
spectrophotometer (Cary Eclipse, Variant, Palo Alto, CA).  Readings were 
obtained with samples in a quartz cuvette at λex = 303 nm and with an emission 
scan of 340-585 nm, both with a 5 nm or 10 nm slit. The PMT voltage was set to 
high.  The maximum emission peak at 371 nm for each spectrum was selected to 
use in the data analysis. OriginPro® 8.6 was used to determine dissociation 
constants for the data obtained by fluorescence quenching.  
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Statistical Analysis 
  An independent-samples two-tailed T-test was used to perform the 
statistical analysis where indicated.  
RESULTS AND DISCUSSION  
Affinity of the cocaine aptamer for cocaine 
 A large range of values have been reported for the affinity of the cocaine 
aptamer for cocaine, ranging from 1nM to 1mM1, 2b, 5, which suggested to us that 
some methods of analysis might provide inaccurate measures of affinity. 
Consequently, we determined the affinities of several versions of the cocaine 
aptamer using two different analytical methods, which were ITC (Fig. 3, 
Supplemental) and fluorescence quenching of 2-aminopurine (2AP) substituted 
aptamers.  By ITC, we tested three aptamer sequences that have been used 
most frequently by others to ensure that the differences in reported affinities are 
not due to differences in aptamer sequence (Table 1).   
 Although the structure of this aptamer is not yet available, the cocaine 
aptamer is frequently represented as shifting from a largely unfolded structure to 
one that is folded when it binds cocaine.6 Such a large shift would be readily 
detected in aptamers with 2-aminopurine (2AP) substituted for A at positions of 
transition between a solution free and stacked configuration because stacking 
quenches the fluorescence of this purine analog.7  We examined a series of 
cocaine aptamer derivatives each with a single adenosine substituted with a 2-
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aminopurine at positions 4, 6, 8, 9, 23, 36 and 38 of the aptamer sequence 
38COC1A (Supplemental materials). The results (Fig 1A) show that most 2AP 
substituted aptamers respond to cocaine with a small increase in fluorescence 
suggesting that the adenosine in that position is less buried in an hydrophobic 
environment after the aptamer binds cocaine.  This result is inconsistent with the 
view that this aptamer shifts from a largely unfolded to a folded structure on 
cocaine binding.  Consistent with the results of others who have shown by 
various means that the 3’ and 5’ ends of the molecule change in their proximity 
with cocaine binding, the 3’ terminal 2AP (A38) shows a relatively large decrease 
in fluorescence on cocaine binding (Fig. 1A).  Thus, it appears that the termini of 
this aptamer come closer together, perhaps forming hydrogen bonds enabling 
A38 to stack with adjacent bases. The changes in fluorescence due to cocaine 
binding were used to determine the dissociation constants of each substituted 
aptamer for cocaine (Fig. 1B).  Although 2AP substitutions are expected not to 
alter DNA structure, we observed the affinity decreased significantly compared 
with the unsubstituted aptamer with 2AP substitutions at positions 4 (P=0.0006) 
and 8 (P=0.01).  These affinities were confirmed by ITC (data not shown). These 
results show that, rather than a large structural change upon binding ligand, the 
cocaine aptamer shifts slightly in structure with most of the shift being an opening 
of the structure to the aqueous environment and with the 3’ base becoming more 
structured, presumably by H-bonding with the 5’ terminal base. 
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Specificity of the cocaine aptamer 
 Many aptamers, including the cocaine aptamer, are reported to be highly 
specific for their targets.  Because this is a very important feature that identifies 
aptamers as highly desirable probes for detecting particular analytes, we tested 
the specificity of the cocaine aptamer. The aptamer’s affinity was established for 
a range of cocaine analogs for which modifications are located variously around 
the molecule.  These analogs included the major metabolites benzolyecgonine, 
ecgonine methyl ester, norcocaine, cocaethylene, ecgonine ethyl ester, ecgonine 
ethyl ester, and anhydroecgonine methyl ester. The results, determined by ITC 
and 2AP fluorescence quenching, show that the aptamer binds to cocaine, 
norcocaine, cocaethylene, and dihydroxy cocaine with about the same affinity 
(Table 2).  The affinities for amethylcocaine and benzoylecgonine are lower than 
for these first four analogs.  There was no evidence for the aptamer binding any 
of the other analogs.  The same results were found for the 36COC3A aptamer 
with slightly higher Kd values (Table 1).  Evaluation of the molecular features 
present in analogs that bound and did not bind to the cocaine aptamer suggests 
that this aptamer fully surrounds cocaine, interacting with every face of the 
molecule (Table 2, Fig. 2B).  These results show that addition of bulk (even a 
methyl group) to the N8 position decreases the affinity of the aptamer (cf. 
norcocaine and cocaine).  The C2-linked methyl or ethyl esters promote binding 
to the aptamer as does the phenylester at C3 (cf. cocaine and anhydroecgonine 
methyl ester).  Although some binding was observed with cocaine derivative 
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containing either a double bond or hydroxyl groups at positions C6 and C7, the 
binding was poor, which showed that the C6-C7 face of the cocaine molecule 
also binds the aptamer.  These results show that all faces of the aptamer bind to 
the cocaine molecule and suggest that the ligand may be buried in the DNA as 
has been observed for other aptamer-ligand interactions.8   
 Originally reported to bind cocaine and neither benzoylecognine nor 
ecognine methyl ester1 the aptamer was later shown to also bind norcocaine.2b 
We show here that it binds cocaine and at least two of its metabolites. This result 
was confirmed by ITC and fluorescence quenching (Fig. 2B). By both assays a 
Kd could be measured for cocaine, norcocaine and cocaethylene.  There were 
no statistical differences in the Kds measured by the two assays for each 
compound. The broader specificity reported here must be considered if the 
aptamer is developed as part of a cocaine sensor. 
Cocaine aptamer interaction with analyte in the presence of biological 
fluids 
 Cocaine is excreted in urine as benzolecognine (35-45%), ecgonine 
methyl ester (32-49%), ecgonine and as unaltered cocaine (1-9%).9  Norcocaine 
is only present in some urine samples in the nM range (~ 60nM).10 Human 
plasma and saliva contain cocaine at a concentration of 3 and 31 µM 
respectively.11 However, urine is the biological matrix of choice because it can be 
obtained non-invasively in sufficient quantities contains detectable concentrations 
of cocaine and its metabolites.12 We examined the effect of urine on the binding 
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of cocaine by the cocaine aptamer (Fig. 3). The 2AP6 substituted aptamer was 
quite tolerant to urine up to 10-25%, The 23AP substituted cocaine aptamer 
showed a progressive decrease in affinity for cocaine as the concentration of 
urine increased (Fig 3B).   
CONCLUSION 
 From a thorough analysis of the cocaine aptamer, its affinity for cocaine 
and its specificity, we propose that this aptamer is not adequate to the task of 
providing a sensitive and specific sensor for cocaine while free in solution. An 
alternative approach for applying this aptamer in a sensor may be immobilization, 
which can significantly increase its affinity.13 
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SUPPORTING INFORMATION 
TABLES 
Table 1: Affinities of commonly used cocaine aptamers for cocaine 
 Analysis method Kd + Std N 
38COC1A ITC 19 ± 7.5 5 
36COC3A ITC 20 ± 3 3 
30COC2A ITC 270 ± 11† 3 
38COC1-2AP23A ITC 14 ± 3.8 6 
38COC1-2AP23A Fluorescence quenching 26 ± 15 3 
 
LEGEND:  Three  commonly  used  cocaine  aptamers were  tested  using  the  isothermal  titration 
calorimetry  (ITC)  for  which  sequences  can  be  found  in  the  Supplementary  materials.    One 
aptamer (38COC1A) was also prepared with a 2AP substitution at position 23 and its affinity for 
cocaine measured by ITC and  2‐aminopurine fluorescence quenching.  
† 
Inter‐assay and Intra‐assay statistical difference at P≤0.0001   
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Table 2:  Specificity of the cocaine aptamer for cocaine and cocaine 
analogs. 
Cocaine analog Kd + Std (µM) 
38COC1A 36COC3A 38COC1-2AP23A
Cocaine 18 ± 8.0  20 ± 3 14 ± 3.8 
Cocaethylene 12 ± 5.4 16 ± 2.3 12 ± 2.8 
Norcocaine 13 ± 3.4 14 ± 4.9 9 ± 0.7 
Benzolyecgonine NB NB NB 
Ecgonine methyl ester NB NB NB 
Ecgonine Ethyl Ester NB NB NB 
Ecgonine NB NB NB 
Anhydroecgonine NB NB NB 
Cocaine-tertiary-N-biotin  NB NB ND 
Cocaine-tertiary-N-Boc  NB NB ND 
Amethyl cocaine 62 ± 21 82 ± 18 ND 
Dithiomethyl cocaine NB ND  ND 
Dihydroxy cocaine  24.3 ND  ND 
 
LEGEND: The affinities of two cocaine aptamers and a 2AP substituted aptamer (position) were 
determined for cocaine, cocaine metabolites and modified cocaine molecules and are expressed 
as Kd in µM. NB=No Binding, ND= Not determined. 
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LEGENDS TO FIGURES 
Figure 1: Effect of cocaine on  the  fluorescence of site‐specific 2AP modified aptamers.   A. A 
series of cocaine aptamers at 4 µM, each modified at a different position, were incubated with a 
saturating concentration of cocaine (200 µM). The fluorescence (at λex = 303 nm; λem = 371) was 
measured  in the presence and absence of cocaine and the difference (without‐with cocaine)  is 
plotted. The buffer was 20 mM Tris.HCl, pH 7.4, 140 mM NaCl, 5 mM KCl. B. A representative 
figure shows the % fluorescence quenching of the 2‐aminopurine (2AP) signal at 371nm with the 
increasing  concentration of  cocaine. The aptamer was modified at  the 23rd position with 2AP 
and  the  dissociation  constant  (K
d
)  obtained  from  this  data was  29.9 µM.  C.  ITC was  used  to 
determine  the  affinities  for  cocaine  of  aptamers  with  site‐specific  2‐aminoputine  (2AP) 
modifications. The unmodified cocaine aptamer is represented with 0 2AP position modification.  
D. The proposed secondary structure of cocaine aptamer6 with the positions of 2AP modification 
identified by the gray‐filled circles.   
Figure 2: Cocaine aptamer specificity. 
A.  Functional  groups  in  cocaine  that  promote  aptamer  recognition  are  circled. Motifs  in  the 
molecules  that  decrease  affinity  for  cocaine  are  identified with  quadrilaterals.  B.  Interassay 
variability in determining the aptamer’s affinity for cocaine and its metabolites.   
Figure 3: Effect of biological fluids on the binding affinities of 2‐aminopurine modified cocaine 
aptamers.     Aptamers modified at position 23 (38COC1‐2AP23A) was tested by ITC its binding 
affinity for cocaine in the presence of urine in a range of concentrations. 
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Supplemental Materials 
Cocaine Aptamers 
 
 
Table 1. All aptamers were purchased from Integrated DNA Technologies (IDT), 
(Coralville, Iowa). Oligonucleotides are listed from 5' end to 3' ends and all 
purchased oligonucleotides were prepared as standard desalted preparations. 
Unmodified cocaine aptamer such as 38COC1A meant 38 nucleotide long 
cocaine (COC) aptamer type 1A. In the case of 2AP modified aptamers, for 
example, 38COC1-2AP4A indicated that 38 nucleotide long cocaine (COC) 
aptamer type-1 had 2AP substituted at the 4th adeninine (A) in the aptamer. All 
2AP modified aptamers had the λex = 303 nm and  λem = 371 nm. 
 
   
Aptamer Sequence (5' - 3') 
38COC1A {Stojanovic and Prada, 
2001} 
GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CGA CA 
30COC2A {Stojanovic and Prada, 
2001} 
GAC AAG GAA AAT CCT TCA ATG AAG TGG GTC 
36COC3A  {Neves et al., 2010} GGC GAC AAG GAA AAT CCT TCA ACG AAG TGG GTC GCC 
38COC1-2AP4A GGG /i2AmPr/ GA CAA GGA AAA TCC TTC AAT GAA GTG GGT CGA 
CA  
38COC1-2AP6A GGG AG/i2AmPr/C AAG GAA AAT CCT TCA ATG AAG TGG GTC 
GAC A  
38COC1-2AP8A GGG AGA C/i2AmPr/AG GAA AAT CCT TCA ATG AAG TGG GTC 
GAC A  
38COC1-2AP9A GGG AGA CA/i2AmPr/G GAA AAT CCT TCA ATG AAG TGG GTC 
GAC A  
38COC1-2AP23A GGG AGA CAA GGA AAA TCC TTC A/i2AmPr/TG AAG TGG GTC 
GAC A  
38COC1-2AP36A GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CG/i2AmPr/ 
CA  
38COC1-2AP38A GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CGA 
C/2AmPr/  
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Synthesis of thiolated cocaine analogs 
 
(1R,2R,3S,5R)-8-tert-butyl 2-methyl 3-(benzoyloxy)-8-azabicyclo[3.2.1]oct-6-ene-
2,8-dicarboxylate (4) 
 To a stirred solution of enol silyl ether 1 in THF (0.10M),  TBAF (1.0 M in 
THF) (1 eq) was added dropwise at 0°C.  The reaction mixture was stirred at this 
temperature for 5 min.  After completion of the reaction, it was quenched with 
water and extracted with EtOAc.  Washed with water, brine and dried over 
MgSO4, followed by filtration and concentration in vacuo.  The residue was 
purified with flash chromatography (2:1 hexanes:EtOAc).  The product was 
obtained as a light yellow oil in 55 % yield. 
 To a stirred mixture of ketone 2 in methanol was added to a solution of 
NaBH4 (5 eq) in methanol (0.10 M) at -30°C.  The reaction was stirred at this 
temperature for 7 hours.  After completion of the reaction, it was quenched with 4 
Figure 1. Synthesis of thiolated cocaine analogs
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M HCl until acidic.  The reaction mixture was concentrated in vacuo.  NH4OH was 
added until the solution was basic, next the residue was extracted with EtOAc 
and washed with water, brine and dried over MgSO4, followed by filtration and 
concentration in vacuo.  The residue was obtained as a clear oil and taken on to 
the next step without further purification. 
 The crude alcoholic product dissolved in MeOH (0.10 M) was added to a 
NaOMe solution (3 eq) and the reaction was stirred for 1 hr at 0°C.  Upon 
completion of the reaction mixture, it was concentrated.  The residue was poured 
into a sat. NH4Cl solution and extracted with Et2O, washed with water, brine and 
dried over MgSO4, followed by filtration and concentration in vacuo.  The residue 
was purified with flash chromatography (1:1 - 1:2 Hexanes:EtOAc).  The product 
was obtained as a clear oil in 31% over two steps. 
 To a stirred mixture of alcohol 3, Et3N (6 eq), DMAP (0.1 eq) in CH2Cl2 
(0.10 M) at 0°C had benzoyl chloride (1.4 eq) added to the reaction.  The 
reaction was heated to reflux and stirred at this temperature for 8 hrs.  Extracted 
with CH2Cl2, washed with water, brine and dried over MgSO4, followed by 
filtration and concentration in vacuo.  The residue was purified with flash 
chromatography (5:1-3:1 Hexanes :EtOAc).  The product was obtained as a clear 
oil in 80 % yield.   
1H NMR (300 MHz, CDCl3) δ  1.51 (s, 9 H), 1.71 (br, 1 H), 2.24 (br, 1 H), 2.97 (m, 
1 H), 3.65 (s, 3 H), 4.73 (m, 2 H), 5.49 (q, J =  9.3 Hz, 1 H), 6.20 (br, 2 H), 7.42 (t, 
J = 7.5 Hz, 2 H), 7.53 (t, J = 7.2 Hz, 1 H), 7.98 (d, J = 7.2 Hz, 2 H); m/z: 410 
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[M+Na]+, 288, 166; HRMS: calcd. for C21H25NO6: 410.1574 [M+Na]+; found 
410.1574.  
(1S,2R,3S,5R,6R,7S)-3-(benzoyloxy)-2-(methoxycarbonyl)-8-methyl-8-
azabicyclo[3.2.1] octane-6,7-diyl bis(4-(methylthio)benzoate) (6) 
 To a stirred solution of olefin 4 in acetone (0.03 M), H2O (0.10 M), and 
TMNO dehydrate (2 eq) had OsO4 (2.5 wt. % in t-BuOH) (0.05 eq) added 
dropwise, and the reaction was stirred for 18 hrs at rt.  The reaction mixture was 
concentrated.   Extracted with EtOAc, washed with water, brine and dried over 
MgSO4, followed by filtration and concentration in vacuo.   The residue was  
taken on to the next step without further purification. 
 To a stirred solution of the crude diol, and DMAP (2.2 eq) in CH2Cl2 (0.05 
M) had 4-(Methylthio)benzoyl chloride (2.1 eq) added at 0°C and the reaction 
warmed up to rt.  The reaction was stirred at this temperature for 8 hrs.  After 
completion, the reaction was quenched with water, extracted with CH2Cl2, 
washed with water, brine, and dried over MgSO4, followed by filtration and 
concentration in vacuo.   The residue was purified with flash chromatography.  
(3:1 - 1:1 Hexanes:EtOAc)  The product was obtained as a clear oil in 38% over 
two steps. 
 To carbamate 5 in CH2Cl2(0.05 M) was added TFA (10 eq), and the 
reaction was stirred for 8 hours at rt.  The reaction mixture was concentrated in 
vacuo.  NH4OH was added until the solution was basic, then the residue was 
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extracted with EtOAc.  Washed with water, brine, dried over MgSO4, followed by 
filtration and concentration in vacuo.  The residue was taken on to the next step 
without further purification. 
 To a stirred a solution of the crude secondary amine, formaldehyde (37 wt. 
% in H2O solution) (1.5 eq) in acetonitrile (0.10 M) along with a flake of 
bromocresol green had NaCNBH3 (1.5 eq) added.  Acetic acid was added 
periodically over 3 hours to maintain a pH of 4 until completion of the reaction.  
NaHCO3(s) was added, followed by addition of 1 M NaOH until the solution was 
basic.  The residue was extracted with EtOAc, washed with water and brine, 
dried over MgSO4, followed by filtration and concentration in vacuo.  The product 
was purified by preparative TLC.  (1:1 Hexanes:EtOAc)  The product was 
obtained as a white solid in 29% over two steps. 
1H NMR (300 MHz, CDCl3) δ  2.20 (br, 1 H), 2.55 (br, 1 H) 2.50 (s, 6 H), 2.78 (s, 
3 H), 3.40 (br, 1 H), 3.64 (br, 1 H), 3.74 (s, 3 H), 3.93 (br, 1 H), 5.15 (m, 1 H),  
5.69 (s, 2 H), 7.10 (dd, J = 8.4 Hz, J= 3.6 Hz, 4 H), 7.45 (t, J = 7.2 Hz, 3 H), 7.55 
(t, J = 7.2 Hz, 2 H), 7.76 (dd, J = 2.7 Hz, J = 8.3, 2 H), 8.06 (d, J = 7.7 Hz, 2 H).  
m/z: 636 [M+H]+, 151. 
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Synthesis of biotinylated cocaine  
  
 
 
(1R,2R,3S,5R)-methyl 3-(benzoyloxy)-8-(5-((3aR,4R,6aS)-2-oxohexahydro-1H-
thieno[3,4-d]imidazol-4-yl)pentanoyl)-8-azabicyclo[3.2.1]oct-6-ene-2-carboxylate 
(7) 
 To carbamate 4 in CH2Cl2(0.05 M) was added TFA (10 eq) and the 
reaction was stirred for 8 hours at rt.  The reaction mixture was concentrated in 
vacuo.  NH4OH was added until the solution was basic, then the residue was 
extracted with EtOAc.  Washed with water, brine, and dried over MgSO4, 
followed by filtration and concentration in vacuo.  The residue was taken on to 
the next step without further purification. 
 To a stirred  solution of the crude secondary amine, Et3N in DMF was 
added NHS-biotin.  The reaction was stirred at 45°C for 8 hours.  The reaction 
mixture was concentrated in vacuo.  The product was purified by preparative TLC 
Figure 2. Synthesis of biotinylated cocaine
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(98:2 EtOAc:MeOH).  The product 7 was obtained as a white solid in 5% over 
two steps.  
1H NMR (400 MHz, CDCl3) δ  0.80-1.80 (m, 10 H), 2.26 (br, 1 H), 2.42 (br, 1 H), 
2.81 (m, 3 H), 3.06 (m, 2 H), 3.51 (m, 1 H), 3.67 (d, J = 8.4 Hz 1 H), 4.90 (m, 1 
H),  5.39 (m, 2 H), 5.45 (m, 1 H), 6.27 (br, 2H), 7.45 (t, J = 7.6 Hz, 2 H), 7.56 (d, J 
= 8.0 Hz, 1 H), 7.99 (d, J = 6.4 Hz, 2H).  m/z: 391 [M-PhCO2H]+, 288, 149   
Isothermal titration calorimetry 
 Isothermal titration calorimetry (ITC) experiments were performed using a 
VP-ITC isothermal titration calorimeter (Microcal, Inc., Northhampton, MA). A 
minimum of three experiments were done for each ligand tested.  In each 
experiment, cocaine was titrated using the computer controlled syringe into the 
sample cell (1.43ml) at 25o C. Cocaine in the syringe and the cocaine aptamer in 
the cell were dissolved in the buffer containing 20mM Tris.HCl- pH 7.4, 140mM 
NaCl and 5mM KCl. The syringe was set at a stirring speed of 310 rpm. After a 
60 seconds initial delay each titration involved an initial 1ul injection followed by 
25 serial injections of 12ul each at intervals of 180s. The raw data obtained in 
each experiment was recorded as (µcal/s) over time (min) and the resulting 
experimental binding data was corrected for the effect of titrating cocaine from 
the syringe into the binding buffer in the sample cell. The thermodynamic 
parameters, ∆H (enthalpy change, kcal/mol), Ka (association constant, M-1), and 
N (number of binding sites per molecule in the sample cell), were obtained using 
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on site binding model in the software (Origin 5.0) provided by Microcal (Microcal, 
Inc). The N was set to variable for all ITC analysis and the data was fit to a single 
site model. Before each titration the oligonucleotide was heated to 88°C for 5 min 
and then cooled to room temperature. Thermodynamic parameters were 
calculated from the equation ∆G = ∆H − T∆S, where ∆G, ∆H, and ∆S are the 
changes in free energy, enthalpy, and entropy of binding, respectively, and T is 
the absolute temperature.  The results of a representative ITC titration is shown 
in Figure 3. 
 
  
  
Figure  3.  Isothermal  titration  calorimetry 
(ITC)  titration  showing  the  binding  of  the 
aptamer GGG AGA CAA GGA AAA TCC TTC 
A/i2AmPr/TG  AAG  TGG  GTC  GAC  A 
(38COC1A‐2AP23A)  with  norcocaine.  The 
data shown in the figure gave a dissociation 
constant (Kd) of 9.3µM.  
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CHAPTER IV: GENERAL CONCLUSIONS AND FUTURE DIRECTIONS 
General Conclusions 
 Detection and quantification of molecules has enormous importance and 
potential in the field of toxicology. The toxicants continue to remain a major 
challenge for the society and public health authorities all over the world and there 
is a continual demand to improve and develop advanced screening methods for 
detection and quantification of molecules that are of toxicological relevance. The 
illicit use of cocaine and other controlled substances remain a major challenge 
for public health authorities and law enforcement agencies. Our attempts to 
comprehensively evaluate the cocaine aptamer for its specificity and sensitivity 
leads to greater understanding of this aptamer towards the continuing 
development of aptamer based miniaturized, portable, regenerable, label free, 
low cost and robust aptasensors for specific, sensitive, rapid, real time detection 
of cocaine and its metabolites in homogeneous and unprocessed biological 
samples. Understanding of the limitations of the current cocaine aptamer will aid 
in the development of  alternative strategies towards the development  of 
fluorescence aptasening platform against the conventional biodetection systems 
for cocaine detection which have several shortcomings of instrumental size, need 
for laboratory settings, high cost of equipment, multistep sample preparation, and 
slow analysis.  
 Ligand specificity plays a vital role in any diagnostic and forensic assay. In 
the case of cocaine aptamer, earlier reports have excluded the specificity of 
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cocaine aptamer for cocaethylene (benzoylecognine ethyl ester) which is an 
important metabolite formed when cocaine is consumed along with ethanol. 
Based on the binding profile of aptamer with cocaine and its metabolites such as 
benzoylecgonine, ecgonine methyl ester, norcocaine, cocaethylene, ecgonine 
and anhydroecgonine methyl ester, the current study determined the structural 
determinants/motifs of cocaine important for cocaine aptamer binding. It was 
hypothesized that if the cocaine aptamer binds selectively to cocaine and some 
of its metabolites then the functional groups that are common to these ligands 
should indicate the determinants of aptamer recognition. Based on the binding 
studies the cocaine molecules interacts on all its faces/sides with the aptamer 
including the non-derivitized part of the cocaine. It was determined that for the 
binding of cocaine aptamer all the three functional groups, N-methyl, carboxyl 
methyl ester, and benzoyl ester, are important. It was also hypothesized that the 
apparently lower affinity of the aptamer for cocaine compared to norcocaine 
could be due to the stearic hindrance caused by N-methyl group. The optimal 
balance of stearic and electronic interactions are seemingly important for the 
affinity of the cocaine aptamer for the cocaine. The information of the functional 
groups important for aptamer recognition will be helpful towards the design of 
aptamer based analytical methods where the knowledge of stearic aspects such 
as the  geometric shape, and  interaction with the functional groups play an 
important role. In the diagnostic and analytical assays, such information will help 
in predicting the ligands that have the potential to cross react, depending upon 
their structural similarity with cocaine. The utilization of the two aptamer 
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sequences and several variants of 2AP substituted  cocaine aptamer confirm that 
the specificity of the aptamer is wider than previously reported.  
 Several schemes can be adopted to transform aptamers into signaling 
aptamers. Most of the aptamers used in sensor technologies are modified post 
selection for their use in analytical, diagnostic, forensic and therapeutic 
applications. We utilized the conformational change of the aptamer upon cocaine 
binding to design a signaling aptamer.  It was hypothesized that if the 2AP was 
introduced in an aptamer in a region/s known to undergo conformational change, 
then the binding event might lead to a change in fluorescence intensity. The 2AP 
was substituted at several positions in the cocaine aptamer. The cocaine binding 
dependent fluorescent results clearly establish the proof of concept that the 
aptamer can be modified by 2AP for fluorescence based method to provide a 
simple and low cost alternative for the detection of cocaine and cocaine 
metabolites in the homogeneous solutions. We observed that not all substitutions 
can be useful for the fluorescence quenching method. Based on the fluorescence 
quenching profile of different 2AP modified cocaine aptamers, the aptamer 
substituted at the  23rd position was evaluated for the fluorescence based 
detection of the cocaine.  During the course of our studies it was also observed 
that the site specific incorporation of the 2AP decreased the affinity of the 
aptamers substituted at the 4th and the 8th position.   
 The ideal method for detecting cocaine should not only be cost effective, 
sensitive, specific, and rapid but also should be able to detect cocaine or its 
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metabolites in complex matrices and unprocessed biological samples. In our 
studies we observed that the biological matrices such as urine provide a 
challenging environment which effects the binding affinity of the aptamer.  In the 
development of fluorescence based methods involving urine, our results show 
the importance of correct concentration of biological fluids such as urine, so as 
not to affect the sensitivity of the aptamer. Urine, if not used in right 
concentrations can drastically interfere with the intended fluorescene output and 
the binding affinity of the aptamer. We tested the aptamer binding in different 
concentrations of urine and determined that 10% urine is best suited for the 
detection of cocaine in the 2AP fluorescence quenching method. Several 
sequences of the cocaine aptamer were tested for their binding with cocaine and 
its metabolites. The 2AP fluorescence quenching was able to detect cocaine in 
both the binding buffer and 10% urine sample. It was also possible to detect 
norcocaine and cocaethylene in binding buffer using the 2AP fluorescence 
quenching.   No doubt, the synergism between cocaine aptamers and 2AP 
fluorescence based technologies offer a low cost aptasensing detection platform 
for detection of cocaine and it metabolites. However, the low affinity and broad 
specificity of the current cocaine aptamer limits it use  in the forensic and 
diagnostic detection of cocaine.   
Future directions  
In our efforts to develop an assay for cocaine detection, it was determined 
that 2AP modified cocaine aptamer can be used for florescence based detection 
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of cocaine. Cocaine aptamer has been reported to undergo large structural 
changes upon cocaine binding. However, in our studies we found relatively small 
2AP fluorescence changes in the regions of the aptamer reported to undergo 
large changes. Further studies may be aimed towards the structural 
characterization to understand the differences between the modified and 
unmodified cocaine aptamer. The nuclear magnetic resonance (NMR) based 
solution structure combined with molecular modeling of the 2AP substituted 
cocaine aptamer complex can provide a comprehensive molecular insights into 
the binding site conformations of the aptamer-ligand complex. Once the NMR 
tertiary structure is elucidated, the molecular dynamic (MD) simulations using the 
structural restraints of the NMR solution structure can be done to determine the 
changes in the structural interface of the 2AP substituted aptamer. We have also 
observed in our experiments, with microcantilever based aptasensing, that the 
affinity of the immobilized aptamer is increased compared to the aptamer binding 
in solution. The understanding of the mechanisms by which immobilization 
enhances the binding affinity would help in exploring the possibilities of improving 
the binding affinities of existing aptamers.   
 Advances in biosensor based technologies involving colorimetric 
techniques, fluorescence labeled probes and micro/ nanofluidic fluidic 
technologies have a growing potential for specific detection and precise 
quantification of analytes. Microfluidic/ nanofluidic devices have gained 
importance due to reduced use of sample consumption, portability, high 
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throughput and speedy processing of samples. The aptasensing approach with 
the use of 2AP incorporation, once established and optimized, can be integrated 
with microfluidics for the need based detection of a wide array of pathogens, 
heavy metals, agrochemicals, mycotoxins and other molecules of toxicological 
relevance important to the healthcare, food and agriculture and biodefense 
industries. As far as cocaine detection is concerned, the need for the 
development of higher sensitivity and higher affinity aptamer is of immense 
importance. Also, the development of high affinity and specificity aptamer for 
benzolyecgonine, which is a major metabolite of urine, will be of immense use in 
diagnostic aptasensing of cocaine in biological matrices. 
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APPENDIX. I 
Development of Aptasensors for the Detection of Cocaine Using 
Microcantilever Based Technology 
Abstract 
 Detection and quantification of molecules has enormous importance and 
potential in the field of scientific development. Advances in colorimetric 
techniques, fluorescence labeled probes and biosensor based technologies have 
resulted in specific detection and precise quantification of analytes. In recent 
years many types of biosensors based applications such as microcantilevers 
have been developed. An in vitro selection and amplification technique, called 
SELEX, has allowed for the discovery of specific oligonucleotide sequences 
referred to as 'aptamers'. Synthetic oligonucleotide aptamers display a high 
affinity binding to recognize virtually any class of target molecules with high 
affinity and specificity and can discriminate between closely related targets 
having small structural differences. The efficacy of aptamer based biosensors 
has been shown on a number of biosensing platforms. Progress in biosensors 
has not only been made possible by the improvement of the biological 
recognition components, such as aptamers, but also due to the implementation 
of efficient signal transducing elements such as microcantilevers.  
Micromechanical cantilever based sensors can provide revolutionary sensitivity 
for forensic detection and identification of controlled substances. The current 
study deals with the validation of the cocaine aptamer  towards the development 
of robust miniature micromechanical cantilever based sensors based on high 
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resolution interferometry coupled with aptamer based receptor layers. The 
successful completion of the research project will serve to advance the 
development of new and improved microcantilever based aptasensors for 
sensitive detection and identification of controlled substances.  
Key words: Aptamer, cocaine, microcantilever, aptasensor. 
 
  
95 
 
 
Introduction and objectives 
 The abuse of cocaine remains a major challenge for public health 
authorities and law enforcement agencies. There is a continuous demand to 
improve and develop advanced screening methods for detection and 
quantification of cocaine, its metabolites and other controlled substances. 
Currently used conventional biodetection systems for cocaine have several 
shortcomings which include their physical size, need for laboratory settings, high 
cost of equipment, large and multistep process of sample preparation, slow 
analysis and lack of simultaneous detection of full range of cocaine and its 
metabolites. More often than not, the sensitivity of the instrument does not fall 
under the minimum detection limits of the National Institute of Drug Abuse 
(NIDA). Against the backdrop of current testing technologies available for 
cocaine detection, the potential of aptasensors for detection of cocaine and its 
metabolites is immense. Aptamers are turning out to be important biological 
components in the biosensor technologies. Synthetic oligonucleotide aptamers 
can be selected with a high affinity binding to recognize virtually any class of 
target molecules and can discriminate between closely related targets. The in 
vitro methods for selection of aptamers, chemical synthesis, on demand 
modification, structural stability, reusability, high throughput, reduced cost, 
minimized material consumption and their ability to multiplex have rendered 
aptamer based detection a very valuable tool to fill in the gaps existing in current 
sensing platforms. The synergism between microcantilevers and aptamers offers 
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a low cost aptasensing detection platform for sensitive and specific detection of 
cocaine and it metabolites.  
This part of the research was designed with the following objectives:  
1. Validation of cocaine aptamer for the development of microcantilever 
based portable, low cost and robust aptasensor for specific, sensitive, 
rapid, real time detection of cocaine.  
 The successful completion of research will set the stage for rapid 
development of aptasensing based nanomechanical devices for a wide array of 
molecules of forensic interest such as explosives and other toxic chemical 
species. 
  
Specific advantages of aptamer functionalized microcantilever based 
detection of cocaine.  
Optical detection methods remain an attractive option in many field 
conditions for both quantitative and semi quantitative analysis. Cantilevers offer 
the capability of label free, specific, sensitive and high throughput analysis of 
analyte. The performance of cantilevers has been compared to the Surface 
Plasmon Resonance [261] and Quartz crystal microbalances [262] in the context 
of label free detection of analytes. The use of labels both covalent and 
noncovalent to detect analytes is a complex and expensive process and can 
affect the binding affinity of aptamer or other detection mechanism. In contrast to 
other label free technologies microcantilevers can be precaliberated for the 
required sensitivity.  Surface Plasmon Resonance in comparison is not sensitive 
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for small molecules like the 12 mers, which are within the sensitivity range of 
microcantilevers [263]. Even though the current label free detection devices are 
not reagent-less, cantilever devices have the potential to be used as an artificial 
nose for detection of cocaine samples in air [264]. Aptamers are specific 
molecular recognition tools for the microcantilever biosensor design.  
Strategies that measure mass, index of refraction or charge resulting from 
analyte binding lead to false positives due to non-specific adsorption of 
contaminants [187]. Aptamer based microcantilever sensor based on binding 
induced surface stress would be specific and reject false positives due to lack of 
non-specific molecular recognition by the aptamer, particularly with a paired 
reference microcantilever.  In our experiments the effects of non-specific 
adsorption, ionic strength, temperature and pH can be minimized by 
simultaneously using the sensing and the reference cantilever in a differential 
sensing platform. 
Microcantilevers can also be used to monitor parameters such as force, 
mass and stiffness which cannot be obtained with other established label free 
biosensors such as SPR. In addition, the label-free property of microcantilever 
detection provides the possibility of microcantilever based microarrays for high-
throughput analysis. Each of the microcantilevers in the array would be 
functionalized with a sensitive aptamer with specificity for cocaine or one of its 
metabolites.  
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Determination of binding of cocaine aptamer on a solid support 
 A 5’thiolated cocaine aptamer labeled with fluorescein at the 3’ end was 
used to determine the binding efficiency of cocaine aptamer on a solid support. 
The aptamer sequence of the sequence 5'-/5ThioMC6-D/GAC AAG GAA AAT 
CCT TCA ATG AAG GTC/36-FAM/-3' was ordered from the IDT DNA 
Technologies Coralville, Iowa, USA.  Phosphate buffered saline (137mM NaCl, 
2.7mM Kcl, 1.8mM KH2PO4, 10mM Na2HPO4) pH 6.5 containing1mM EDTA was 
used a coupling buffer. Supfhydryl-Bind Polystyrene 1x8 Stripwell Plates 
(Corning Cat# 2510) were used as a test platform to replicate the aptamer 
binding on the gold plated microcantilevers.  Berthold Mithras LB 940 was used 
to determine the fluorescence. The number of reactive sites in the sulfhydryl 
binding plate was 1x1014. The diameter of the bottom of the well was 6.4 mm that 
gave an area of 32 mm2, which in turn gave the number of reactive sites in each 
well to 32x1012 which was equal to 0.053 nmole/well. For the 100 µl of 100 µM 
aptamer with MW of 10186 the calculated concentration to be used of aptamer is 
0.5 µM. In the experiment 0.5 µM and 1 µM concentrations were used. Based on 
the mean values the binding that was observed was 21% and 34% when 1 and 
0.5 µM concentration of the thiol labeled aptamer were used (Fig. 1). 
Robustness of aptamer bound to solid support for its repeated use 
 Analysis was done determine if the cocaine aptamer bound to polystyrene 
surface shows activity after repeated use. 5'-/5ThioMC6-D/GAC AAG GAA AAT 
CCT TCA ATG AAG GTC/36-FAM/-3' was purchased from IDT, Coralville, Iowa, 
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USA. Phosphate buffered saline 137 mM NaCl, 2.7 mM KCl, 1.8 mM KH2PO4, 10 
mM Na2HPO4) pH 6.5 containing 1 mM EDTA was used as a coupling buffer to 
bind the aptamer to the sulphydryl-Bind Polystyrene 1x8 Stripwell Plates 
(Corning Cat# 2510). Cocaine [3-(Benzoyloxy)-8-methyl-8-azabicyclo(3.2.1) 
octane-2-carboxylic acid methyl ester] (Cerilliant, Cat#C-008)  binding to the 
aptamer was determined in cocaine binding buffer (20 mM Tris-HCl, 140 mM 
NaCl, 5 mM KCl pH 7.4). The Cary Eclipse fluorescence spectrophotometer was 
used to read the fluorescence output. The fluorescence output was obtained from 
a maximum of 0.053 nmole of bound aptamer to the bottom of the well assuming 
that 100% has bound. Even, against the high background of fluorescence, 
cocaine did seem to quench the fluorescence signal upon repeated aptamer 
washing and rinsing cycles. The experiments showed that not only did the 
aptamers remained bound to the solid support upon repeated wash/rinse cycles 
but they also the cocaine aptamer showed activity in bound state. Quenching of 
the cocaine aptamer stabilized after 15 minutes of cocaine exposure to the 
aptamer (Fig. 2). 
Evaluation of the effect of acetonitrile on the binding parameters of 
Cocaine with cocaine aptamer 
 Cocaine is received as a solution in acetonitrile.  Therefore, if the 
acetonitrile is nor first removed, and depending on the initial concentration of 
cocaine and the necessary dilution for the experiment, some acetonitrile will be 
present during the measurement.  Thus, experiments were conducted to 
determine the effect of acetonitrile on the binding of cocaine to the cocaine 
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aptamer (5'- GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT CGA CA- 3'). 
The results from the series of ITC experiments show that aptamer binding is not 
affected (dissociation constant in the range of range of 16-26 µM) if the 
acetonitrile concentration is kept below 2-3%.  However, higher concentrations of 
acetonitrile reduce the affinity of aptamer binding by as much as 10 fold.  The 
dissociation constant (16.2 µM) obtained in these experiments in the absence of 
acetonitrile is much lower than the reported Kd of 100 µM for cocaine aptamer, 
which suggests that acetonitrile might have been present at concentrations 
higher than 2-3% during the previously reported measurements.  The results 
show that for comparative results the acetonitrile concentration in the buffers for 
different experiments must be kept constant and preferably below 2-3% (Fig. 3). 
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Validation of dithiomethylcocaine for its binding to cocaine aptamer and 
the hybridization experiments with poly A and poly T 
 Several experiments were done in coordination with experiments of 
collaborator Pranav Shrotriya and his students who were examining the ability of 
the microcantilever device derivatized with the cocaine aptamer to detect 
cocaine.  These experiments independently determined the Kd for hybridization 
of the polyA and polyT used in the cantilever experiments and determine the Kd 
for interaction of dithiodimethylcocaine to the aptamer. Dithiodimethylcocaine 
was being used as a means of attaching cocaine to the microcantilever in order 
to examine the reverse condition for interaction of cocaine and the aptamer, with 
the cocaine on the solid support instead of the aptamer. 
Dithiomethylcocaine (Fig. 4a) binding to the cocaine aptamer (GGG AGA 
CAA GGA AAA TCC TTC AAT GAA GTG GGT CGA CA) was tested using ITC. 
Dithiomethylcocaine, (obtained from Dr. Kraus Laboratory) showed weak binding 
with cocaine aptamer (Fig. 4b) with a calculated dissociation constant of 95.2 µM. 
The low affinity of the cocaine aptamer for dithiomethylcocaine could be because 
of the stearic hindrance caused by the thiomethyl groups at the non-derivitized 
part of the cocaine molecule. 
 Hybridization experiments were performed using 30 nt poly A and poly T.  
Hybridization Buffer, 20× SSPE, 0.2 M NaCl, 7% SDS, 40% Formamide, 0.1% 
NP40, pH 7.4, was used in the experiments. The results of the experiment 
showed two binding sites in the hybridization of poly A with poly T (Fig. 5). Poly A 
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and poly T hybridize with two binding sites and the two dissociation constants 
obtained in the analysis were 19.8 nM and 0.25 nM respectively.  
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Fig 1: Determination of binding of cocaine aptamer on a solid support. A 
5’thiolated cocaine aptamer labeled with fluorescein at the 3’ end of the 
sequence  5'-/5ThioMC6-D/GAC AAG GAA AAT CCT TCA ATG AAG GTC/36-
FAM/-3' was used.  Phosphate buffered saline (137mM NaCl, 2.7mM Kcl, 1.8mM 
KH2PO4, 10mM Na2HPO4) pH 6.5 containing1mM EDTA was used a coupling 
buffer. Supfhydryl-Bind Polystyrene Stripwell Plates were used as a test platform 
to replicate the aptamer binding on the gold plated microcantilevers.  
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Fig 2: Effect of time on the fluorescence quenching of the cocaine aptamer 
bound to solid support. The florescence of 5'-/5ThioMC6-D/GAC AAG GAA 
AAT CCT TCA ATG AAG GTC/36-FAM/-3' was recorded in the presence of 
10mM cocaine over time. The Cary Eclipse fluorescence spectrophotometer was 
used to read the fluorescence output.  
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Fig 3. Evaluation of the effect of acetonitrile on the binding parameters of 
cocaine with cocaine aptamer. (a) Isothermal titration calorimetry (ITC) was 
performed to determine the equilibrium constants for the cocaine aptamer. The 
data shown in this figure gave a Kd = 11 µM; (b): Effect of acetonitrile on the 
dissociation constant of the cocaine aptamer. The affinity of the cocaine aptamer 
for cocaine was measured by ITC in the presence of a variety of concentrations 
of acetonitrile 
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Fig 4. (a) Structure of Dithiomethylcocaine. (b) Validation of dithiomethylcocaine 
for its binding to cocaine aptamer using ITC. Dithiomethylcocaine binding to the 
cocaine aptamer (GGG AGA CAA GGA AAA TCC TTC AAT GAA GTG GGT 
CGA CA) was tested using ITC. Dithiomethylcocaine, bound with cocaine 
aptamer with a calculated dissociation constant of 95.2 µM.  
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Fig 5. ITC graph showing the two binding sites of the Hybridization of poly 
A and poly T. Hybridization experiments were performed using 30 nt poly A and 
poly T.  Hybridization Buffer, 20× SSPE, 0.2 M NaCl, 7% SDS, 40% Formamide, 
0.1% NP40, pH 7.4, was used.  Poly A and poly T hybridize with two binding 
sites and the two dissociation constants obtained in the analysis were 19.8 nM 
and 0.25 nM respectively.  
 
  
Published: August 29, 2011
r 2011 American Chemical Society 14696 dx.doi.org/10.1021/la202067y | Langmuir 2011, 27, 14696–14702
ARTICLE
pubs.acs.org/Langmuir
Aptamer Functionalized Microcantilever Sensors for Cocaine
Detection
Kyungho Kang,† Ashish Sachan,‡ Marit Nilsen-Hamilton,‡ and Pranav Shrotriya*,†
†Department of Mechanical Engineering and ‡Department of Biochemistry, Biophysics and Molecular Biology, Iowa State University,
Ames, Iowa 50011, United States
’ INTRODUCTION
The U.S. Department of Health and Human Services (HHS)1
has established a standard of cocaine metabolite cutoﬀ levels of
150 ng/mL and 100 ng/mL for initial screening and conﬁrma-
tory cutoﬀ levels, respectively. Current methods of initial screen-
ing and identifying biological samples for drugs of abuse can
match the new standard for detection and identiﬁcation of
cocaine metabolite. For instance, enzyme multiplied immunoas-
say technique (EMIT)24and enzyme-linked immunosorbent
assay (ELISA)57 are the two predominant enzyme-base im-
munoassays utilized for screening tests. In both techniques,
detection of the controlled substance is based on optical absor-
bance resulting from enzymatic activity. Gas chromatography
coupled with mass spectrometry (GC-MS)810and high-perfor-
mance liquid chromatography (HPLC)1113 can achieve detec-
tion levels required for conﬁrmatory identiﬁcation of controlled
substances. These techniques require extensive sample prepara-
tion, a long performance time, and/or specialized instrumenta-
tion to validate drug presence. The sample often must be sent to
the lab, which results in a signiﬁcant delay in identiﬁcation.12,1422
Aptamer-based biosensors (often called aptasensors) have been
investigated as an alternative method to overcome these draw-
backs. Sensitivity and detection times of conventional and aptamer-
based techniques are compared in Figure 1.
Aptamers are synthetic oligonucleotides that recognize and
bind to their respective targets. They are selected and character-
ized by SELEX (systematic evolution of ligands by exponential
enrichment) process and proposed as an alternative to antibodies
and other biomimetic receptors. Aptamers are much smaller than
their protein (antibody) counterparts, and unlike antibodies, ligand
binding is often accompanied by large structural changes in the
aptamers that can be utilized for detection of the target.20 Aptamers
have been selected that recognize two drugs of abuse, which are
cocaine20 and codeine,23 and many medicinal drugs and anti-
biotics including theophylline,24 tobramycin,25 neomycin,26
kanamycin,27 dopamine,28 chloramphenicol,29 streptomycin,30 and
tetracycline.31 The aﬃnities (Ka) of these aptamers are in the
range of 105 to 107 M1.
In 2001, Stojanovic and co-workers20 reported a DNA-based
aptamer that undergoes speciﬁc binding with cocaine. It was
hypothesized that binding of the aptamer with cocaine results in a
change of aptamer structure from an unstructured single-
stranded DNA to a three-way stem.20,32 The aptamer was used
for cocaine detection through ﬂuorescent and colorimetric
sensors, and a 10 μM detection limit was reported.20,32 Baker
et al.33 used the same DNA aptamer in electronic aptamer-based
(E-AB) sensors and measured a dissociation constant (Kd) of
90 μM for cocaine/aptamer binding and detection limits of
below 10 μM for cocaine molecules. White et al.34 investigated
the inﬂuence of aptamer surface coverage on the performance of
electrochemical aptamer-based sensor (E-AB cocaine sensor) in
detection of cocaine molecules and reported that an increase in
surface coverage resulted in lower response from E-AB sensors
for similar levels of cocaine concentrations. They concluded that
this phenomenon occurred due to unfavorable interaction arising
between neighboring aptamers. In the E-AB sensor, measured
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ABSTRACT: A cocaine-speciﬁc aptamer was used as a receptor
molecule in a microcantilever-based surface stress sensor for
detection of cocaine molecules. An interferometric technique
that relies on measuring diﬀerential displacement between two
microcantilevers (a sensing/reference pair) was utilized to
measure the cocaine/aptamer binding induced surface stress
changes. Sensing experiments were performed for diﬀerent con-
centrations of cocaine from 25 to 500 μM in order to deter-
mine the sensor response as a function of cocaine concentration.
In the lower concentration range from 25 to 100 μM, surface
stress values increased proportionally to coverage of aptamer/
cocaine complexes from 11 to 26 mN/m. However, as the cocaine concentration was increased beyond 100 μM, the surface stress
values demonstrated a weaker dependence on the aﬃnity complex surface coverage. On the basis of a sensitivity of 3 mN/m for the
surface stress measurement, the lowest detectable threshold for the cocaine concentration is estimated to be 5 μM. Sensing
cantilevers could be regenerated and reused because of reversible thermal denaturation of aptamer.
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response is dependent on the number of aptamers undergoing
conformal changes on binding with cocaine molecules. Thus,
White et al.34 hypothesized that the optimal surface coverage for
E-AB sensor will correspond to surface-immobilized aptamer
spacing such that a single aptamer chain can undergo a con-
formational change with little or no interaction with neighboring
molecules. However, the low aﬃnity between cocaine and aptamer
limited the detection threshold to 10 μM cocaine concentration.
Freeman et al.35 and Golub et al.36 conducted QD-based
optical sensing as well as electrochemical sensing of cocaine by
employing a split cocaineaptamer and pyrene modiﬁcation to
create supramolecular complexes. They demonstrated detection
limits of 1 μM for FRET-based sensing and 10 μM for the
amperometric response of the system respectively. Madru et al.37
demonstrated that the anticocaine aptamer-based sorbent can be
used for the selective extraction of cocaine from human plasma.
They showed close to 90% of extraction recovery with 3.5 μM of
the detection limit of cocaine. Shlyahovsky et al.38 proposed the
ampliﬁed analysis of cocaine by an autonomous aptamer-based
machine and obtained a detection limit for cocaine of 5 μM for
60 min operating time for the machine. Li and Zhang et al.39,40
utilized a split aptamer that reassembles into the full tertiary
structure in the presence of target. AuNPs then diﬀerentiate
between these two states through surface plasmon resonance-
based color change. This colorimetry was able to detect a con-
centration as low as 2 μM cocaine solution.
The aptamer has also been reported to have a range of aﬃnities
for binding with cocaine with reported Ka values between 1.25 
104 and 5 103M1.20,32,34,41 In summary, the cocaine aptamer has
been used in a variety of diﬀerent platforms, but low aﬃnity between
the cocaine and aptamer molecules limits the detection threshold
between 1 and 10 μM.
Micromechanical cantilever (MC) based sensors have been
investigated for detection of chemical and biological species.42,43
An MC intended for chemical or biological sensing is normally
modiﬁed by coating one of the cantilevers with a responsive
phase that exhibits high aﬃnity to the targeted ligand. The
surface stress change induced due to the binding of ligand on
the sensitized surface is resolved for detection. Potential uses of
cantilever transducers in biosensors, biomicroelectromechanical
systems (Bio-MEMS), proteomics, and genomics are intriguing
trends in advanced biomedical analyses.4447 When antibodies
or small DNA fragments were immobilized on one side of a
cantilever, the presence of complementary biological species
produced cantilever deﬂections.45,47 On the basis of the deﬂec-
tion behavior of MCs, even very small mismatches in receptor
ligand complementarity could be detected. A single base pair
mismatch was detected by oligonucleotide hybridization experi-
ments performed on a cantilever surface.44,45
In this work, an aptamer-functionalized microcantilever is
utilized for detection of cocaine molecules. The MC sensor for
cocaine detection relies on resolving surface stress changes
associated with formation of aﬃnity complexes between aptamer
and cocaine molecules as shown schematically in Figure 2. An
interferometric technique was utilized to measure the surface
stress induced bending of the sensing cantilever. The principle of
surface stressmeasurement is schematically presented inFigure 3.
The sensor consists of two microlens arrays (MLA1 and MLA2)
andmicrocantilevers (sensing/reference pair) arranged such that
a pair of light beams can reﬂect from the microcantilevers. As a
result, the two beams collect a phase diﬀerence proportional to
the diﬀerential displacement of the two beams. Monitoring of
the phase diﬀerence as a function of time is utilized to determine
the development of diﬀerential surface stress between the two
cantilevers.48 The unique advantages of the diﬀerential surface
Figure 1. Comparisons of sensitivity and time for conventional and
aptamer-based sensing techniques.20,3235,3740,5357
Figure 2. Schematic representation of the sensing strategy for cocaine
detection.
Figure 3. Optical circuit of diﬀerential surface stress sensor. Laser
wavelength is 635 nm. A pair of microlens arrays with lens of 240 and
900 μm diameters; and pitches of 250 μm and 1 mm, respectively were
used to direct the beams toward the sensing/reference pair.
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stress sensor are as follows: Direct detection of diﬀerential surface
stress eliminates the inﬂuence of environmental disturbances such as
nonspeciﬁc adsorption, changes in pH, ionic strength, and especially
temperature. Sensitivity of the sensor is independent of distance
between the sensing surface and detector, which results in the sensor
being amenable for miniaturization and enables an array of sensors
to be easily fabricated on a single MEMS device.
’MATERIALS AND METHODS
Cocaine aptamers with the sequences of 50- GGGA GAC AAG GAA
AAT CCT TCA ATG AAG TGG GTC GACA- 30 and 50-GAC AAG
GAA AAT CCT TCA ATG AAG TGG GTC-30 were purchased from
Integrated DNA Technologies (IDT, Coralville, Iowa). Aptamer bind-
ing aﬃnity for the cocaine target was measured by isothermal titration
calorimetry (ITC) in PBS (20 mMTris.HCl, pH 7.4, 140 mMNaCl and
5mMKCl) using the ﬁrst sequence. Thiolated version of second
sequence was used for surface stress sensor experiments. Cocaine
samples dissolved in acetonitrile were purchased from Sigma Aldrich
(St. Louis, Missouri). As received, the cocaine samples were diluted in
deionized water and vaporized in the vacuumed centrifuge in order to
achieve desired concentration of acetonitrile in the solution.
Isothermal titration calorimetry (ITC) experiments were performed
using a VP-ITC isothermal titration calorimeter (Microcal, Inc., North-
hampton, MA). In each experiment, 600 μM cocaine was titrated using
the computer-controlled syringe into the sample cell (1.43 mL) contain-
ing 20 μM cocaine aptamer at 25 C. Both aptamer and cocaine were
dissolved in PBS in the presence of various concentrations of acetoni-
trile. Before each titration, the oligonucleotide was heated to 92 C for
5 min in the titration buﬀer and then cooled to room temperature for
60 min. The syringe was set at a stirring speed of 310 rpm. After a 60 s
initial delay, each titration involved an initial 1 μL injection followed by
25 serial injections of 12 μL each at intervals of 300 s. The raw data
obtained in each experiment were corrected for the eﬀect of titrating
cocaine from the syringe the sample cell containing the buﬀer and
various concentrations of acetonitrile but no aptamer. The thermody-
namic parameters were calculated using a one-site binding model in the
software (Origin 5.0) provided by Microcal (Piscataway, New Jersey).
Sensing and reference cantilevers were coated respectively with the
cocaine aptamer and a control DNA consisting of the same bases as the
cocaine aptamer but with their sequence scrambled. Thiol-modiﬁed
cocaine aptamers and control DNA were purchased from IDT
(Coralville, Iowa). Gold-coated microcantilevers with nominal dimen-
sions of 500 μm length, 100 μm width, and 1 μm thickness were
purchased from Nanoandmore.com (Lady’s Island, South Carolina).
Thickness of the cantilevers showed signiﬁcant deviation from the manu-
facturer speciﬁcation; therefore, the exact dimension of the cantilevers used
for sensing experiments was determined to be vary from 0.8 to 1.5μm from
measured values of normal stiﬀness and natural frequency.48
Microcantilevers were cleaned by the Piranha solution (70% H2SO4
and 30%H2O2) for several minutes, rinsed in deionized water, and dried
in the gentle N2 ﬂow. Scanning electron micrographs were obtained
before and after the cleaning to ensure that the integrity of gold ﬁlm is
not aﬀected during the cleaning procedure. Thiol-modiﬁed DNAs were
heated until 60 C to cleave any disulﬁde bonds and mixed with the
saline sodium citrate buﬀer (20  SSC), pH 7.4, to obtain a 0.5 μM
aptamer solution. Cleaned microcantilevers were immersed in the
aptamer solution for three hours in order to immobilize the thiol-
modiﬁed DNAs on the gold-coated surface. Functionalized microcanti-
levers were immersed in 6-mercapto-1-hexanol solution (3 mM con-
centration) for one hour to displace any adsorbed DNA.
The functionalized sensing and reference cantilevers weremounted in
the diﬀerential surface stress sensor and exposed to diﬀerent concentra-
tions of cocaine from 25 to 500 μM in PBS to determine the sensor
response as a function of the cocaine concentration. After the sensing
experiments, the sensing and reference cantilevers were heated in
deionized water at 80 C to regenerate the aptamer sequence. The
regeneration allows the sensing cantilevers to be used a number of times
and each cantilever was used for at least three sensing experiments.
’RESULTS
Isothermal titration calorimetry tests were used to determine
the aﬃnity between cocaine molecules and the DNA aptamer. A
representative test result is plotted in Figure 4A. We found that
the aptamer’s binding aﬃnity is highly sensitive to the presence of
acetonitrile, which is the solvent of available cocaine standard
solutions (Figure 4B). The dissociation constant (Kd) of the
currently available cocaine aptamers is between 11 and 22 μM for
very low or minimal acetonitrile concentration as shown in
Figure 4B, but for concentrations of acetonitrile above 3 %, the
dissociation constant rises to greater than 200 μM. This observa-
tion probably explains why the aptamer has been reported to
have a large range of aﬃnities.20,34,41
Figure 4. Isothermal titration calorimetry (ITC) was performed to determine the equilibrium constants for the cocaine aptamer. (A) Kd of the cocaine
aptamer for cocaine in the presence as a function of acetonitrile concentration. (B) Representative ITC data shown in this ﬁgure gave a Kd = 11 μM.
14699 dx.doi.org/10.1021/la202067y |Langmuir 2011, 27, 14696–14702
Langmuir ARTICLE
Diﬀerential surface stress developed on the functionalized
cantilevers was measured as a function of cocaine concentrations
in PBS. Sensor response was measured for 10 diﬀerent cocaine
concentrations: 0 (pure buﬀer), 25, 50, 75, 100, 150, 200, 300,
400, and 500 μM. At each concentration, the sensing experi-
ments were repeated three times to assess the repeatability of the
experimental measurement. Two typical experimental observa-
tions of surface stress development during direct sensing corre-
sponding to a cocaine concentration of 50 μM and pure buﬀer
are plotted in Figure 5. As shown in the Figure 5, the surface
stress starts developing as soon as the cocaine solution is injected
in the sensor and saturates to a constant value after a period of
approximately 25 min. For PBS alone, there is no surface stress
buildup indicating the speciﬁcity of sensor response to cocaine
solution.
The saturated surface stress values were recorded for each
sensing experiment and are plotted as a function of cocaine
concentration in Figure 6. As reported above, the cocaine
aptamer/cocaine molecule binding was found to depend on
the acetonitrile concentration. Therefore, all solutions for the
sensing experiments were prepared to ensure that acetonitrile
concentration was below 2%. Measured surface stress values at
diﬀerent cocaine concentrations are ﬁt to a Langmuir isotherm,
and the curve ﬁt with 95% conﬁdence intervals49 is also plotted in
Figure 6 to highlight the repeatability of the sensor response.
Microcantilever sensors were regenerated after the sensing
experiments and the response of regenerated cantilevers were
found to be similar to the original cantilevers.
Sensitivity of the surface stress measurements was determined
to be 3 mN/m based on the response measured in the absence of
cocaine. On the basis of the sensitivity assumption and ﬁt for
the experimental data, the lowest detectable threshold for the
cocaine concentration is estimated to be 5 ( 8.9 μM (95% con-
ﬁdence interval). Lowest detection threshold for aptamer func-
tionalized microcantilever based sensing approach is limited
through two fundamental limits: ﬁrst, the aﬃnity of cocaine
aptamer to cocaine molecules and, second, the smallest detect-
able mechanical deformation caused by the cocaine/aptamer
binding. The current aptamer has low aﬃnity for cocaine mole-
cules and thus limits the detection threshold to roughly 110 μM
over all the diﬀerent detection thresholds. The detection threshold
computed from the current experiments is similar to that reported
from using this aptamer in other detection platforms.20,3235,40 The
unique advantages of the microcantilever-based sensing over an-
other sensing platform is the small size of sensing element which
ensures that only a small volume of testing solution (on the order
of 100 μL) and shorter time required for sensing. Diﬀerential
measurement of the cantilever deformation also ensures that the
inﬂuence of nonspeciﬁc binding from the solutionmay be eliminated.
Savran et al.46 investigated the surface stress developed due to
the binding between DNA aptamers and protein (Thermus
aquaticus (Taq) DNA polymerase). They reported dissociation
constant of 15 pM for the DNA/protein binding and obtained
cantilever deﬂections between 3 and 32 nm (0.99.6 mN/m) at
pM concentrations of proteins. We found that the dissociation
constant of cocaine and its aptamer is about a million times
higher than those for proteinaptamer complexes; therefore, a
larger concentration of cocaine molecules is required to elicit a
similar bending response from the cantilevers.
In order to understand the relationship between aptamer
cocaine binding and surface stress development, the dissociation
constant measured by ITC was used to predict the surface cover-
age of cocaineaptamer complexes for each cocaine concen-
tration.
α
C
C þ Kd
where α is surface coverage of cocaine aptamer on sensing
cantilever and C is the cocaine concentration. A Kd of 20 μM
32
was utilized to estimate the fraction of initial aptamer molecules
that form the cocaine aptamer complexes. The fraction of
cocaine/aptamer complexes can also be used to estimate the
inﬂuence of surface stress change as a function of surface cover-
age of molecules.
The measured surface stress is plotted as a function of the
calculated fraction of the aptamercocaine complexes in Figure 7.
Surface stress induced by binding of the ligand on the receptor-
coated surface is hypothesized to be linearly dependent on
the surface coverage of receptor/ligand complexes.42,50 A linear
ﬁt assuming that measured surface stress changes (Δσ) are
directly proportional to coverage of cocaineaptamer com-
plexes, Δσ = k 3α, and is also plotted on the curve to test the
validity of hypothesis. As indicated in the plot, the developed
Figure 5. Surface stress developments during direct sensing for 0
(buﬀer only) and 50 μM cocaine.
Figure 6. Saturated surface stress values as a function of cocaine
concentrations. A curve ﬁtting with Langmuir isotherm along the
experimental data and the 95% conﬁdence intervals (red line) around
the ﬁt. The coeﬃcient of determination, R2, for the Langmuir isotherm
ﬁt was found to be 0.86.
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surface stress may be considered proportional to coverage of the
cocaineaptamer complexes when the proportion of the surface
coverage is smaller than 90% (corresponding to 100 μM cocaine
concentration). As the surface coverage of aptamercocaine
complexes approaches and becomes larger than 90%, the devel-
oped surface stress is higher than predicted by proportionality
assumption. This transition may be due to the nature of inter-
molecular repulsion between the cocaineaptamer complexes.
The data presented here show that the surface stress can be
considered linearly dependent on the ligand/receptor complexes
for low surface coverage only.
The exact form of the relationship depends on the nature of
interactions between the complexes. In the experiments, forma-
tion of the aptamercocaine complexes on the sensing cantilever
leads to expansion of the aptamer-coated surface and suggests
that cocaine binding to aptamer leads to increased repulsion
between the neighboring chains. The interchain repulsion mod-
els developed to explain surface stress induced by hybridization
of single-stranded DNA may be applied to explain the surface
stress developed due to repulsion between cocaine/aptamer
complexes. Interchain repulsion between the chains may arise
either from electrostatic interactions of negative charges along
the DNA chains or from hydration forces. In the current
experimental conditions, electrostatic interactions between neighbor-
ing strands are not expected to be signiﬁcant due to shielding eﬀect of
cations in PBS solution.50 The hydration forces may be primarily
responsible for the repulsive interactions and are reported to have an
exponential dependence on the interchain separation.5052 The
nonlinear dependence of the hydration forces on interchain separa-
tion may explain the surface stress dependence on surface coverage
shown in Figure 7. These data can be utilized to estimate the
functional form of interchain repulsion between the cocaine
aptamer complexes and also to determine themechanism underlying
the surface stress generation.
’CONCLUSIONS
In this study, the existing cocaine aptamer was tested by ITC
to determine its aﬃnity for cocaine. From these studies, we found
that acetonitrile, the common solvent for cocaine standards,
causes a signiﬁcant decrease in aﬃnity of the aptamer for cocaine.
By maintaining the acetonitrile concentration below 2%, we
realize a 5-fold increase in sensitivity of the aptamer compared
with published data and with results from our own studies.
Experimental results presented here have demonstrated a
proof-of-concept for cocaine detection with aptamer-functional-
ized microcantilevers at low cocaine concentrations. The surface
stress generated due to binding of cocaine molecules to the
existing cocaine aptamer was determined. In the range of cocaine
concentrations 25500 μM, surface stress changes were found
to be 951 mN/m.
The sensor is able to detect cocaine with the lowest detectable
concentration down to 5( 8.9 μM (1.5 ( 2.7 μg/mL) at room
temperature and is similar to the detection threshold obtained
using the aptamer on other detection platforms. The low aﬃnity
of the aptamer for cocaine limits the detection threshold. The
aptamer-functionalized cantilever could be regenerated after
each sensing experiment and demonstrated no change in sensi-
tivity and speciﬁcity in subsequent experiments. The experimen-
tal data also showed that the surface stress generated during the
sensing experiments is not directly proportional to the surface
coverage of aptamer/cocaine complexes.
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APPENDIX II: Targeted reversibly attenuated probes: In-vivo imaging with 
intracellular RNA probes 
Abstract  
 Most measurements of cellular responses to toxins involve cell death, 
either as a measure of the response or to isolate the molecules that indicate the 
response.  Often the cells need to be incubated for long time periods with toxin 
before the response is observed.  The ability to detect early cellular changes to 
toxins in real time requires a functional probe to be present in the cell from which 
a signal can be derived. This is possible with the use aptamers, which have the 
ability to specifically bind target molecules as do antibodies, but that also function 
inside living cells. The targeted reversely attenuated probe (TRAP) is an 
aptamer-based biosensor in which aptamer activity can be regulated by a 
specific nucleic acid sequence such as in a full length mRNA. The central portion 
of the TRAP, between the aptamer and the attenuator, is complementary to a 
target nucleic acid. Thus the TRAP can give a real-time signal in a living cell of 
the change in level of a specific mRNA.  Here we report the development of a 
TRAP that can be regulated by full length Lcn2 mRNA. Lcn2 is an acute-phase 
response gene. This TRAP has the potential to be expressed as an intracellular 
probe to detect increased levels of Lcn2 mRNA synthesized in response to 
toxins. Current efforts are directed to develop a FRET assay system using the 
TRAP concept for real-time rapid detection of gene expression changes in-vivo in 
response to toxins and other treatments. 
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Testing the allosteric regulation of ATP (Adenosine-5'-triphosphate) -
Neomycin CLAMP (cis-linked aptamers for medical or microanalytical 
procedures) 
  In the process of the development of TRAPs (The targeted 
reversely attenuated probe) the allosteric regulation of ATP (Adenosine-5'-
triphosphate)-Neomycin CLAMP (5'-
GGCCUGGGCGAGAAGUUUAGGCCUUGGGUUGGGAAGAA 
ACUGUGGCACUUCGGUGCCAGCAACCC- 3') was tested using ITC. For the 
CLAMP design, two RNA aptamer sequences were linked into a single molecule 
to form CLAMPs. The CLAMPS were generated by in-vitro transcription followed 
by gel purification. Secondary structure predictions for the CLAMP are shown in 
Fig 1. Previous studies had provided evidence for allostery  (Stodola B.A:  
Interactions of rationally designed multiple-aptamer constructs [M.S. Thesis]. 
United States-- Iowa: Iowa State University: 2003) and these experiments were 
done to test the allosteric effect upon binding of these dual aptamer constructs to 
the ligands, increasing the binding of one aptamer by selectively binding other 
parts of the construct. Sequential ITC runs were conducted to evaluate the 
binding of ATP and neomycin to the CLAMP independently or in the presence of 
the other ligand. The binding parameters of ATP to the CLAMP in the absence of 
neomycin showed that ATP bound with the CLAMP with the N value of ~1.03 and 
the Kd of 5.4 µM (Fig 2). In the presence of neomycin, ATP had a dissociation 
constant of 3 µM. Similarly, CLAMP showed binding to neomycin in with a 
dissociation constant of 0.2 µM.  There was an increase in binding affinity of ATP 
with CLAMP in the presence of neomycin. However, the differences in Kd are not 
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sufficiently significant to demonstrate the allosteric regulation of CLAMP. It is 
significant to note that the cis-linked aptamers retained their binding affinity to 
their respective ligands. This is an important finding towards the development of 
dual aptamer based TRAPS where the aptamers will be cis-linked in addition to 
the sequence of the attenuator and the regulatory component.  
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Fig 1: Secondary structures of CLAMP as predicted by mfold. For the 
CLAMP design, two RNA aptamer (ATP and Neomycin) sequences were linked 
into a single molecule to form CLAMPs. ATP (Adenosine-5'-triphosphate)-
Neomycin CLAMP (5'-
GGCCUGGGCGAGAAGUUUAGGCCUUGGGUUGGGAAGAA 
ACUGUGGCACUUCGGUGCCAGCAACCC- 3').  
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Fig 2: Representative figure showing the ligand binding (ATP) to the 
CLAMP using. ITC. Isothermal titration calorimetry (ITC) was performed to 
determine the functionality of CLAMP. The data shows the binding of ATP to 
CLAMP. The data shown in this figure gave a Kd  of 5.4 µM. 
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Synthesis of different Malachite Green (MG) TRAPs.  
  A TRAP that can be regulated by full length Lcn2 mRNA was synthesized 
and tested for its functionality. Lcn2 is an acute-phase response gene. In this 
TRAP the 38 nt malachite green RNA aptamer (MGA) was modified through 
truncations and mutations. A microarray analysis was used to identify the 25nt 
antisense oligonucleotide that targets position 501-525 of full length Lcn2 mRNA. 
Several rationally designed TRAPs were synthesized and gel purified (Table 1). 
MG aptamer (32MG1) was used. The number of intervening sequences were 
either 20 or 25. The 501 or 561 indicated the 5' end target position of intervening 
sequence of TRAP. For example, 32MG1-20-561-9 indicates TRAP has a 20nt 
intervening sequence that targets Lcn2 mRNA from 561 to 580. The attenuator 
sequence of 9, 10, 11 or 12 was used to determine the exact length of the 
attenuator sequence for the proper functioning of the TRAP.  The MG aptamer 
sequences were used here for 6 different MG TRAPs. Of the 6 MG TRAPS 
tested 32MG1-25-501-9 seemed to be best with almost 20 fold increase from its 
background (Fig 1).  This work was performed by Torry Cong (Cong X: 
Development of aptamer based targeted reversibly attenuated probes [Ph.D. 
Thesis]. United States -- Iowa: Iowa State University: 2006) and Meiguan Yang.  
 Several other modifications of the Malachite Green (MG 1) TRAP were 
designed and synthesized (Table 2). These MG TRAPS had a 20 nt long 
intervening sequence that targeted the Lcn2 mRNA sequence from 501 to 520. 
The sequence of the attenuator was varied in each of the TRAPS. The TRAPs 
were further tested in a fluorescence based assay to determine the affects of 
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different attenuator sequences.  For all the TRAPS the fold increase ranged from 
~3 to ~6 (Fig. 1&2).  Of the 9 MG TRAPS tested 32MG1-20-501-9.2, 32MG1-20-
501-9.3 and 32MG1-20-501-9.7 showed more than fivefold increase over no 
addition.  32MG1-20-501-9.2, 32MG1-20-501-9.7 and 32MG1-20-501-9.7 
showed more then 2.5-fold increase over the yeast total RNA. 32MG1-20-501-
9.1and 32MG1-20-501-9.7 seemed to the best when compared with the signal 
obtained from the incubation with yeast RNA or no other RNA addition.  32MG1-
20-501-9.7 gave the highest ratio of Lcn2 signal over yeast total RNA. 
Development of a tandem linked dual aptamer based tobramycin-
theophylline TRAP (Targeted Reversely Attenuated Probe) 
 Because malachite green was found to be toxic to cells, it was necessary 
to develop TRAPs that bound different ligands for visualizing TRAP activation.  
Therefore, for the next step in developing a TRAP that can function in cells, a 
TRAP was designed to recognize ligands that are not toxic to cells.  In this 
design, the central portion of the TRAP (26TOB1A-33THE1A-25-Utc501-9), 
between the aptamer and the attenuator, is complementary to a target nucleic 
acid (Fig 3). Thus the TRAP can give a real-time signal in a living cell of the 
change in the level of a specific mRNA. The 83nt long sequence (5'-
GGCGAUACCAGCCACUUGGUUUAGGUAAUGAGUGGCCCUUGGCA 
GCGUCACAGCUCCUUGGUUCUUCCAUAUUCGACGCUGCC-3') was 
designed to fulfill the secondary structure requirements of the TRAP design (Fig 
4). The tobramycin and theophylline aptamers were linked in tandem with the 
attenuator regulating the activity of the theophylline aptamer. The tobramycin 
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component of aptamer forms the top portion whereas the theophylline 
component of the aptamer forms the middle portion and the antisense sequence 
along with attenuator forms the lower part of structural sequence. The TRAP 
design was tested using sequential ITC experiments. The experiments showed 
that theophylline did not bind to the TRAP in the absence of regulatory DNA.  
However, tobramycin bound to the TRAP with the dissociation constant of 
45.7nM. In the presence or regulatory DNA the TRAP binds to the 400nM and 
1uM with the tobramycin and theophylline, respectively.   
Development of concatenated neomycin-tobramycin TRAP 
Due to the large background in fluorescence, the TRAP design needed to also 
include the option for FRET in order to visualize the outcome of hybridization with 
RNA. For this, the 75nt long sequence (23NeoB-27TOBA-16-Utc501-9) (5'-
GGACUGGGCGA 
GAAGUUUAGUCCGGCACGAGGUUUAGCUACACUCGUGCCUCCUUGGUUC
UUCCAUGGCACGAGU-3') design was found to fulfill the neomycin B-
Tobramycin TRAP requirements with a shorter 16nt long antisense sequence. 
The neomycin-B component of the aptamer forms the 5' end of the TRAP design 
whereas the tobramycin component of the aptamer forms the middle portion and 
the antisense sequence along with attenuator are towards the 3' end of the 
structural sequence (Fig. 5). The antisense component of the TRAP bound to its 
complimentary sequence with the calculated dissociation constant of 4.8 µM. 
Also, the neomycin bound to the TRAP with a dissociation constant of 138 nM. 
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However, the TRAP did not bind to tobramycin in the presence of regulatory 
DNA. Therefore, this TRAP therefore, was not carried forward for any further 
testing.  
 Development of concatenated poly A linked neomycin-tobramycin TRAP 
 This TRAP has a poly A linker between the neomycin and tobramycin 
aptamer. The 79nt long sequence (23Neo1A-AAAA-27TOB3A-16-Utc501-9) (5'-
GGACUGGGC 
GAGAAGUUUAGUCCAAAAGGCACGAGGUUUAGCUACACUCGUGCCUCCU
UGGUUCUUCCAUGGCACGAGU-3') fulfilled the secondary structure design 
requirements of a neomycin B-Tobramycin TRAP. The details of the most likely 
structures generated by MFold (Zuker M: Mfold web server for nucleic acid 
folding and hybridization prediction. Nucleic Acids Research 2003, 31:3406-
3415) are presented in Fig. 6. The neomycin-B component of the aptamer forms 
the 5' end of the TRAP design whereas the tobramycin component of the 
aptamer forms the middle portion and the antisense sequence along with 
attenuator are towards the 3' end of the structural sequence. This run of 
sequential ITC was done to see the binding parameters of neomycin after the 
sense oligo and tobramycin is already titrated. The TRAP bound to neomycin 
with the dissociation constant of 118.5 nM. Table 2 summaries the sequential 
binding affinity of this TRAP to the regulatory DNA, neomycin and the 
tobramycin. Both neomycin and tobramycin regulate each other's binding affinity. 
Both show higher affinity to the TRAP when the other ligand has been previously 
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titrated. The TRAP is functional, however has very low affinity for tobramycin. 
This TRAP might be useable in a FRET-based assay if the tobramycin 
concentration is maintained below 5-10 µM. The presence of the regulatory DNA 
(RNA surrogate) specifically unexpectedly increased the affinity of the TRAP for 
neomycin compared with for tobramycin. More work needs to be done to develop 
these TRAPs.  
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Fig 1. Fluorescence measurements of the interaction of different MG 
TRAPs with Lcn2 mRNA,  regDNA , and Yeast RNA.  
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Fig 2. Fluorescence measurements of the interaction of different MG 
TRAPs with  Lcn2 mRNA,  regDNA , and Yeast RNA.   
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Fig 3. The dual aptamer TRAP concept. The targeted reversely attenuated 
probe (TRAP) is an aptamer-based biosensor in which aptamer activity can be 
regulated by a specific nucleic acid sequence such as in a full length mRNA. In 
this design, the central portion of the TRAP (26TOB1A-33THE1A-25-Utc501-9), 
between the theophylline aptamer and the attenuator, is complementary to a 
target nucleic acid.  
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Fig 4. Mfold secondary structures of the tobramycin-theophylline TRAP. 
The 83nt long sequence (5'-
GGCGAUACCAGCCACUUGGUUUAGGUAAUGAGUGGCCCUUG 
GCAGCGUCACAGCUCCUUGGUUCUUCCAUAUUCGACGCUGCC-3') was 
designed to fulfill the secondary structure requirements of the TRAP design. The 
tobramycin and theophylline aptamers were linked in tandem with the attenuator 
regulating the activity of the theophylline aptamer. 
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Fig 5. MFold secondary structures of the concatenated neomycin-
tobramycin TRAP. The 75nt long sequence (5'-
GGACUGGGCGAGAAGUUUAGUCCGGCACGAG 
GUUUAGCUACACUCGUGCCUCCUUGGUUCUUCCAUGGCACGAGU-3') was 
designed to found to fulfill the neomycin -tobramycin TRAP requirements with a 
16nt long antisense sequence. The neomycin component of the aptamer forms 
the 5' end of the TRAP design whereas the tobramycin component of the 
aptamer forms the middle portion and the antisense sequence along with 
attenuator are towards the 3' end of the structural sequence 
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Fig 6. Mfold secondary structures of the concatenated poly A linked 
neomycin-tobramycin TRAP. The TRAP has a poly A linker between the 
neomycin and tobramycin aptamer. The TRAP has 79nt long sequence 
(23Neo1A-AAAA-27TOB3A-16-Utc501-9) (5'-GGACUGGGC 
GAGAAGUUUAGUCCAAAAGGCACGAGGUUUAGC UACACUCGU 
GCCUCCUUGGUUCUUCCAUGGCACGAGU-3'). The neomycin-component of 
the aptamer forms the 5' end of the TRAP design whereas the tobramycin 
component of the aptamer forms the middle portion and the antisense sequence 
along with attenuator are towards the 3' end of the structural sequence. 
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Table 1: 
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Table 3: Table showing the binding affinities of the sense sequence,  
neomycin and tobramycin in a sequential ITC experiments. 
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